Drugname	药物名	靶点	Gene Name#AA Mutation	基因	变异	染色体位置(GRCh37)	支撑1	支撑2	FDA批准上市	CFDA批准上市	疗效/副作用	癌种	推荐等级
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	CDK8#p.A155V	CDK8	p.A155V	13:26956958..26956958	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	CDK8#p.D103N	CDK8	p.D103N	13:26923311..26923311	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.D594G	BRAF	p.D594G	7:140453154..140453154	PMID: 18794803	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.D594G	BRAF	p.D594G	7:140453154..140453154	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.D594H	BRAF	p.D594H	7:140453155..140453155	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.D594N	BRAF	p.D594N	7:140453155..140453155	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.D820E	KIT	p.D820E	4:55599334..55599334	PMID: 19461405	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3#p.D835?	FLT3	p.D835?	13:28592642..28592642	PMID: 22368270	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	.	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3#p.D835H	FLT3	p.D835H	13:28592642..28592642	PMID: 23969938	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	.	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3#p.D835H	FLT3	p.D835H	13:28592642..28592642	PMID: 22368270	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	.	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3#p.D835H	FLT3	p.D835H	13:28592642..28592642	PMID: 23969938	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	.	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3#p.D835Y	FLT3	p.D835Y	13:28592642..28592642	PMID: 22368270	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	.	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	CDK8#p.E165Q	CDK8	p.E165Q	13:26956987..26956987	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.E490K	KIT	p.E490K	4:55592144..55592144	PMID: 21325067	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	CDK8#p.E66Q	CDK8	p.E66Q	13:26911771..26911771	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3#p.F691L	FLT3	p.F691L	13:28601359..28601359	PMID: 23969938	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	.	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.G469A	BRAF	p.G469A	7:140481402..140481402	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.G469E	BRAF	p.G469E	7:140481402..140481402	PMID: 18794803	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.G469R	BRAF	p.G469R	7:140481403..140481403	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.G596D	BRAF	p.G596D	7:140453148..140453148	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.K601E	BRAF	p.K601E	7:140453134..140453134	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.K642E	KIT	p.K642E	4:55594221..55594221	PMID: 18936790	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	CDK8#p.L142M	CDK8	p.L142M	13:26927985..26927985	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.L576P	KIT	p.L576P	4:55593661..55593661	PMID: 18936790	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	CDK8#p.R150T	CDK8	p.R150T	13:26928010..26928010	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.R462K	BRAF	p.R462K	7:140481423..140481423	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	CDK8#p.R65K	CDK8	p.R65K	13:26911769..26911769	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	ARAF#p.S214C	ARAF	p.S214C	X:47426121..47426122	http: //www.jci.org/articles/view/72763; 24569458	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.V559A	KIT	p.V559A	4:55593610..55593610	PMID: 18936790	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.V559D	KIT	p.V559D	4:55593610..55593610	PMID: 18936790	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.V560D	KIT	p.V560D	4:55593613..55593613	PMID: 18936790	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.V600K	BRAF	p.V600K	7:140453136..140453137	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF#p.V600R	BRAF	p.V600R	7:140453136..140453137	.	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	耐药性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.W557R	KIT	p.W557R	4:55593603..55593603	PMID: 12960119	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT#p.Y553N	KIT	p.Y553N	4:55593591..55593591	PMID: 21969494	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT::consequence::inframe_deletion:577-579	KIT	KIT inframe deletion (577-579)	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 20970876	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 25810463	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	BRAF__.	BRAF	BRAF fusion	7:140434346..140434580..exon1,140439601..140439756..exon2,140449076..140449228..exon3,140453064..140453203..exon4,140453976..140454043..exon5,140476701..140476898..exon6,140477780..140477885..exon7,140481365..140481503..exon8,140482810..140482967..exon9,140487337..140487394..exon10,140494097..140494277..exon11,140500151..140500291..exon12,140501201..140501370..exon13,140507749..140507872..exon14,140508681..140508805..exon15,140534398..140534682..exon16,140549900..140550022..exon17,140624355..140624553..exon18	PMID: 238900088; 20526349; 24727320	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3::consequence::inframe_variant:572-603	FLT3	FLT3-ITD	13:28578138..28578321..exon1,28588578..28588704..exon2,28589283..28589403..exon3,28589716..28589848..exon4,28592593..28592736..exon5,28597476..28597624..exon6,28598987..28599090..exon7,28601214..28601388..exon8,28602304..28602435..exon9,28608013..28608138..exon10,28608208..28608361..exon11,28608427..28608554..exon12,28609621..28609820..exon13,28610061..28610190..exon14,28611311..28611435..exon15,28622401..28622590..exon16,28623510..28623684..exon17,28623761..28623921..exon18,28624221..28624369..exon19,28626671..28626821..exon20,28631473..28631609..exon21,28635993..28636216..exon22,28644617..28644759..exon23,28674594..28674697..exon24	PMID: 19389879; 22368270	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	FLT3::consequence::inframe_variant:572-603	FLT3	FLT3-ITD	13:28578138..28578321..exon1,28588578..28588704..exon2,28589283..28589403..exon3,28589716..28589848..exon4,28592593..28592736..exon5,28597476..28597624..exon6,28598987..28599090..exon7,28601214..28601388..exon8,28602304..28602435..exon9,28608013..28608138..exon10,28608208..28608361..exon11,28608427..28608554..exon12,28609621..28609820..exon13,28610061..28610190..exon14,28611311..28611435..exon15,28622401..28622590..exon16,28623510..28623684..exon17,28623761..28623921..exon18,28624221..28624369..exon19,28626671..28626821..exon20,28631473..28631609..exon21,28635993..28636216..exon22,28644617..28644759..exon23,28674594..28674697..exon24	PMID: 23613521	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT:550-592;627-664;788-828;829-860	KIT	KIT (550-592;627-664;788-828;829-860)	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18936790; 20372153	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT:788-828	KIT	KIT mutation in exon 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 23840364	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT:550-592;449-514	KIT	KIT mutation in exon 9 or 11	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 22270258	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KIT::wildtype:.	KIT	KIT wildtype	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	ASCO 2011 (abstr 10009)	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	PMID: 25294897	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 25810463	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	NRAS:.	NRAS	NRAS oncogenic mutation	1:115251105..115251285..exon1,115252179..115252359..exon2,115256410..115256609..exon3,115258660..115258831..exon4	PMID: 25294897	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	PDGFRA::wildtype:.	PDGFRA	PDGFRA wildtype	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	ASCO 2011 (abstr 10009)	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	RAF1__.	RAF1	RAF1 fusion	3:12625962..12626166..exon1,12626335..12626490..exon2,12626610..12626762..exon3,12627169..12627308..exon4,12629079..12629146..exon5,12632286..12632483..exon6,12633196..12633301..exon7,12641179..12641317..exon8,12641640..12641788..exon9,12641876..12641924..exon10,12645624..12645798..exon11,12647689..12647808..exon12,12650254..12650432..exon13,12650721..12650844..exon14,12653438..12653571..exon15,12660003..12660270..exon16	PMID: 20526349	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	RAF1:over	RAF1	RAF1 overexpression	3:12625962..12626166..exon1,12626335..12626490..exon2,12626610..12626762..exon3,12627169..12627308..exon4,12629079..12629146..exon5,12632286..12632483..exon6,12633196..12633301..exon7,12641179..12641317..exon8,12641640..12641788..exon9,12641876..12641924..exon10,12645624..12645798..exon11,12647689..12647808..exon12,12650254..12650432..exon13,12650721..12650844..exon14,12653438..12653571..exon15,12660003..12660270..exon16	PMID: 24375110	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	VEGFA:amp	VEGFA	VEGFA amplification	6:43738393..43739059..exon1,43738933..43739059..exon2,43742045..43742139..exon3,43742067..43742139..exon4,43745195..43745412..exon5,43746186..43746283..exon6,43746615..43746665..exon7,43748458..43748532..exon8,43748458..43748550..exon9,43748458..43748601..exon10,43749682..43749799..exon11,43749682..43749834..exon12,43752267..43752333..exon13,43752267..43752349..exon14,43752267..43752415..exon15,43752333..43752415..exon16	PMID: 24687604	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Sorafenib	Sorafenib (索拉非尼)	VEGFR; PDGFR; KIT; RAF	VHL:.	VHL	VHL oncogenic mutation	3:10183481..10183881..exon1,10188187..10188330..exon2,10191460..10191699..exon3	PMID: 18635227	NCT00110019: 黑色素瘤; NCT00300885: 非小细胞肺癌; NCT00449033: 非小细胞肺癌; NCT00541021: 胰腺癌; NCT00558636: 非小细胞肺癌; NCT00863746: 非小细胞肺癌; NCT01234337: 乳腺癌; NCT02474290: 急性髓性白血病	是	是	敏感性增加	肝癌; 甲状腺癌; 肾癌	I
Regorafenib	Regorafenib (瑞戈非尼)	KIT; PDGFR; RAF; RET; VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT:449-514;550-592;627-664;664-714;788-828	KIT	KIT mutation in exon 9;11;13;14 or 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	FDA;Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. J Clin Oncol. 2017; 389: 56-66.	NCT01774344:Phase 3:Active, not recruiting:Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.	是	否	敏感性增加;部分存在严重的肝脏毒性;建议治疗前和用药期间进行肝功能监测;如果肝癌患者服用索拉非尼之后病情仍然恶化，那么加用瑞戈非尼可使死亡风险下降38%，它也因此获得美国FDA批准用于二线治疗。	肝癌还没批;结直肠癌、胃肠道间质瘤中国获批	I
Regorafenib	Regorafenib (瑞戈非尼)	KIT; PDGFR; RAF; RET; VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	FDA guidelines;Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. J Clin Oncol. 2017; 389: 56-66.	NCT01774344:Phase 3:Active, not recruiting:Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.	是	否	敏感性增加;部分存在严重的肝脏毒性;建议治疗前和用药期间进行肝功能监测;如果肝癌患者服用索拉非尼之后病情仍然恶化，那么加用瑞戈非尼可使死亡风险下降39%，它也因此获得美国FDA批准用于二线治疗。	肝癌还没批;结直肠癌、胃肠道间质瘤中国获批	I
Regorafenib	Regorafenib (瑞戈非尼)	KIT; PDGFR; RAF; RET;  VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PDGFRA:552-596;631-668;814-854	PDGFRA	PDGFRA (552-596;631-668;814-854)	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	NCCN guidelines;Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. J Clin Oncol. 2017; 389: 56-66.	NCT01774344:Phase 3:Active, not recruiting:Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.	是	否	敏感性增加;部分存在严重的肝脏毒性;建议治疗前和用药期间进行肝功能监测;如果肝癌患者服用索拉非尼之后病情仍然恶化，那么加用瑞戈非尼可使死亡风险下降40%，它也因此获得美国FDA批准用于二线治疗。	肝癌还没批;结直肠癌、胃肠道间质瘤中国获批	I
Nivolumab	Nivolumab (纳武单抗;O药)	PD-1	CD274:over	CD274	CD274 overexpression	9:5456063..5456175..exon1,5457068..5457430..exon2,5462823..5463131..exon3,5462823..5463227..exon4,5465488..5465616..exon5,5466759..5466839..exon6,5467829..5467912..exon7	PMID: 25452452/NCT03383458: 肝癌;Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389: 2492-2502.	NCT03143270:Early Phase 1:Recruiting:No publish||NCT03572582:Phase 2:Recruiting:No publish||NCT03203304:Phase 1:Recruiting:No publish||NCT03299946:Phase 1:Recruiting:No publish||NCT02423343:Phase 1|Phase 2:Recruiting:No publish||NCT03071094:Phase 1|Phase 2:Recruiting:No publish||NCT02859324:Phase 1|Phase 2:Recruiting:No publish||NCT03511222:Phase 1:Not yet recruiting:No publish||NCT03222076:Phase 2:Recruiting:No publish||NCT03418922:Phase 1:Recruiting:No publish||NCT03382886:Phase 1:Recruiting:No publish||NCT02576509:Phase 3:Active, not recruiting:No publish	是	否	敏感性增加;具有一定的胚胎毒性;可能引起肝肾功副作用;FDA批准该药作为晚期肝癌的二线治疗	膀胱癌; 非小细胞肺癌; 黑色素瘤; 霍奇金淋巴瘤; 肾癌; 头颈癌	I
Lenvatinib	Lenvatinib (乐伐替尼)	FGFR;RET; PDGFR; VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	SDHB#p.V140F	SDHB	p.V140F	1:17355093..17355103	https: //doi.org/10.2217/ije-2016-0015	NCT03433703:Phase 2:Recruiting:No publish||NCT03418922:Phase 1:Recruiting:No publish||NCT03006926:Phase 1:Recruiting:No publish||NCT02953743:Phase 1:Active, not recruiting:No publish||NCT01761266:Phase 3:Active, not recruiting:No publish	是	否	敏感性增加;可能引起胚胎毒性、肝肾功影响以及心力衰竭等;2018《柳叶刀》发表的研究显示，对于晚期肝癌患者，一种新靶向药——乐伐替尼（Lenvatinib）的疗效与索拉非尼不相上下，而且对乙肝相关的肝癌疗效更佳。	甲状腺癌;肾癌	I
AMG-386	Trebananib (AMG-386)	Ang1;Ang2	.	.	.	.	NCT00872014:Phase 2:Completed:No publish	.	是（非本癌种）	否	.	卵巢癌;腹膜癌;输卵管癌	III
ABC-294640	ABC-294640	SK2	.	.	.	.	NCT02939807:Phase 2:Recruiting:No publish	.	否	否	.	先进的胆管癌临床;肝癌临床	III
ABT-751	ABT-751	.	.	.	.	.	NCT00036959:Phase 1:Completed:Fox E; Maris JM; Cohn SL; Goodspeed W; Goodwin A; Kromplewski M; Medina D; Xiong H; Krivoshik A; Widemann B; Adamson PC; Balis FM. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. doi: 10.1007/s00280-009-1218-z. Epub 2010 Jan 1.	.	否	否	.	肺癌;非小细胞肺癌	III
ABT-869	ABT-869	VEGF;PDGFR	FLT3	FLT3	FLT3 mutation	13:28578138..28578321..exon1,28588578..28588704..exon2,28589283..28589403..exon3,28589716..28589848..exon4,28592593..28592736..exon5,28597476..28597624..exon6,28598987..28599090..exon7,28601214..28601388..exon8,28602304..28602435..exon9,28608013..28608138..exon10,28608208..28608361..exon11,28608427..28608554..exon12,28609621..28609820..exon13,28610061..28610190..exon14,28611311..28611435..exon15,28622401..28622590..exon16,28623510..28623684..exon17,28623761..28623921..exon18,28624221..28624369..exon19,28626671..28626821..exon20,28631473..28631609..exon21,28635993..28636216..exon22,28644617..28644759..exon23,28674594..28674697..exon24	NCT00517920:Phase 2:Completed:No publish	.	否	否	敏感性增加	血液恶性肿瘤;实体瘤	III
Adavosertib	Adavosertib（AZD-1775;MK-1775）	WEE1	.	WEE1	WEE1	11:9595430..9596066..exon1,9597424..9597650..exon2,9597450..9597650..exon3,9597766..9597850..exon4,9598023..9598216..exon5,9598678..9598820..exon6,9603068..9603235..exon7,9606794..9606910..exon8,9606978..9607084..exon9,9607985..9608176..exon10,9608247..9608413..exon11,9609985..9610199..exon12	NCT02465060:Phase 2:Recruiting:No publish	.	否	否	.	神经胶质瘤;实体瘤	III
Adecatumumab 	Adecatumumab (MT-201)	IgG1;EpCAM (CD326)	.	EPCAM 	EPCAM 	2:47596287..47614167	NCT00866944:Phase 2:Completed:No publish||NCT00866944:Phase 2:Completed:No publish	.	否	否	.	前列腺癌;乳腺癌;结肠癌;胃癌;卵巢癌;胰腺癌;肺癌	III
Afatinib	Afatinib	EGFR	EGFR#p.D807H	EGFR	p.D807H	7:55249121..55249121	NCT02465060:Phase 2:Recruiting:No publish	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	肺癌	II
Afatinib	Afatinib	ERBB3	ERBB3#p.G284R	ERBB3	p.G284R	12:56481922..56481922	PMID: 27044931	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	ERBB3	ERBB3#p.G284R	ERBB3	p.G284R	12:56481922..56481922	ASCO 2015 (abstr e15516)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.G719A	EGFR	p.G719A	7:55241708..55241708	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.G719C	EGFR	p.G719C	7:55241708..55241708	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.G719D	EGFR	p.G719D	7:55241708..55241708	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.G719S	EGFR	p.G719S	7:55241708..55241708	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.L747S	EGFR	p.L747S	7:55242470..55242470	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.L861P	EGFR	p.L861P	7:55259524..55259524	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.L861Q	EGFR	p.L861Q	7:55259524..55259524	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.L861R	EGFR	p.L861R	7:55259524..55259524	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB3	ERBB3#p.R103G	ERBB3	p.R103G	12:56478851..56478851	PMID: 27044931	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB3	ERBB3#p.R103G	ERBB3	p.R103G	12:56478851..56478851	ASCO 2015 (abstr e15516)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.S768I	EGFR	p.S768I	7:55249005..55249005	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.S811C	EGFR	p.S811C	7:55249134..55249134	.	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	NCCN	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 27553514	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB3	ERBB3#p.V104M	ERBB3	p.V104M	12:56478854..56478854	PMID: 27044931	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR::consequence::inframe_deletion:729-761	EGFR	EGFR exon 19 deletions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR::consequence::inframe_insertion:729-761	EGFR	EGFR exon 19 insertions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 22753918, 25589191	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	EGFR	EGFR::consequence::inframe_insertion:729-761	EGFR	EGFR exon 19 insertions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	ESMO 2012 (abstr 1289)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	AACR 2014 (abstr CT228)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 20142587, 22418700, 23632474	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 27044931	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB2	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB2	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547;ASCO 2017 (abstr 9071)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	ERBB4	ERBB4__.	ERBB4	ERBB4 fusion	2:212248289..212248795..exon1,212251567..212251885..exon2,212252659..212252727..exon3,212285155..212285346..exon4,212286721..212286839..exon5,212288869..212289036..exon6,212293122..212293218..exon7,212295659..212295835..exon8,212426617..212426823..exon9,212483891..212484010..exon10,212488636..212488779..exon11,212495176..212495329..exon12,212522468..212522563..exon13,212530037..212530212..exon14,212537878..212537992..exon15,212543766..212543919..exon16,212566681..212566901..exon17,212568818..212568929..exon18,212570032..212570126..exon19,212576764..212576911..exon20,212578249..212578383..exon21,212587107..212587269..exon22,212589790..212589929..exon23,212615353..212615439..exon24,212652739..212652894..exon25,212812144..212812351..exon26,212989466..212989638..exon27,213403162..213403304..exon28	PMID: 24727320	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
Afatinib	Afatinib	NRG1	NRG1__.	NRG1	NRG1 fusion	8:31497450..31498255..exon1,32406194..32406354..exon2,32453335..32453533..exon3,32463069..32463211..exon4,32472021..32472092..exon5,32474342..32474413..exon6,32505186..32505913..exon7,32579470..32579570..exon8,32585456..32585606..exon9,32585456..32585650..exon10,32599515..32599603..exon11,32600182..32600261..exon12,32600182..32600336..exon13,32607068..32607112..exon14,32611879..32612002..exon15,32611913..32612002..exon16,32613910..32614057..exon17,32616813..32616964..exon18,32617707..32617934..exon19,32617707..32617978..exon20,32620725..32620906..exon21,32621255..32621970..exon22	AACR 2016 (abstr 2631)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;注意胚胎毒性	肺癌	II
AG-013736	Axitinib (阿昔替尼)	VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	NCT01273662:Phase 2:Completed:No publish;NCT01744249: 神经内分泌癌;PMID: 25686603	.	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌	II
AG-013736	Axitinib (阿昔替尼)	VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	VHL:.	VHL	VHL oncogenic mutation	3:10183481..10183881..exon1,10188187..10188330..exon2,10191460..10191699..exon3	NCT01273662:Phase 2:Completed:No publish;NCT01744249: 神经内分泌癌;PMID: 18635227	.	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌	II
Alvocidib	Alvocidib	CDK1;CDK2;CDK4;CDK5;CDK6;CDK7;CDK8;CDK9;EGFR	.	.	.	.	NCT00087282:Phase 2:Completed:No publish||NCT00012181:Phase 1:Completed:No publish	.	否	否	.	非小细胞肺癌	III
Anlotinib	Anlotinib（安罗替尼）	RTK;VEGFR2(KDR);VEGFR3(FLT4)	.	.	.	.	NCT02809534:Phase 2:Recruiting:No publish	.	否	否	.	非小细胞肺癌;转移性结肠直肠癌	III
Apatinib	Apatinib（阿帕替尼）	VEGFR	.	.	.	.	NCT03092895:Phase 2:Recruiting:No publish||NCT02702323:Phase 2|Phase 3:Not yet recruiting:No publish||NCT02727309:Phase 1|Phase 2:Recruiting:No publish||NCT02942329:Phase 1|Phase 2:Recruiting:No publish||NCT02772029:Phase 1|Phase 2:Unknown status:No publish||NCT03511703:Phase 2:Not yet recruiting:No publish||NCT03261791:Phase 2:Recruiting:No publish||NCT03114085:Phase 2:Not yet recruiting:No publish||NCT03046979:Phase 2:Recruiting:No publish||NCT02329860:Phase 3:Active, not recruiting:No publish||NCT01192971:Phase 2:Completed:No publish	.	否	是（非本癌种）	.	晚期胃癌;肝癌三期临床性价比比较高，对索拉菲尼不适用的可以推荐	I
ARQ-087	ARQ-087	VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	.	.	.	.	NCT03230318:Phase 2:Recruiting:No publish||NCT01752920:Phase 1|Phase 2:Active, not recruiting:No publish||NCT01656265:Phase 1:Completed:No publish||NCT00988741:Phase 2:Completed:No publish||NCT00802555:Phase 1:Completed:No publish	.	否	否	.	肝内胆管癌	III
ARQ-197	ARQ-197 （Tivantinib）	MET	.	MET	MET	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	NCT02029157:Phase 3:Completed:No publish	.	否	否	.	实体瘤	III
ASLAN-001	ASLAN-001（varlitinib）	ERBB2;EGFR	.	.	.	.	NCT03499626:Phase 1|Phase 2:Recruiting:No publish	.	否	否	.	实体瘤;晚期或转移性胆道癌	III
Atezolizumab	Atezolizumab（阿特珠单抗;T药）	PD-1	CD274 overexpression	CD274	CD274 overexpression	9:5456063..5456175..exon1,5457068..5457430..exon2,5462823..5463131..exon3,5462823..5463227..exon4,5465488..5465616..exon5,5466759..5466839..exon6,5467829..5467912..exon7	NCT03434379:Phase 3:Recruiting:No publish	.	是（非本癌种）	否	敏感性增加	局部晚期或转移性尿路上皮癌	I
ATG-008	ATG-008	TORC1;TORC2	.	.	.	.	NCT03591965:Phase 2:Not yet recruiting:No publish	.	否	否	.	HBV阳性晚期肝细胞癌	II
Avastin	Avastin;bevacizumab(贝伐单抗) 	VEGF	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT00507585:Phase 1:Completed:No publish;PMID: 24232489, 2485933	NCT00028990: 乳腺癌; NCT00088894: 胰腺癌; NCT00109239: 乳腺癌; NCT00110214: 前列腺癌; NCT00262067: 乳腺癌; NCT00281697: 乳腺癌;NCT00324987: 胃肠道间质瘤; NCT00333775: 乳腺癌; NCT00373256: 乳腺癌; NCT00391092: 乳腺癌; NCT00448591: 乳腺癌; NCT00450203: 胃癌; NCT00486759: 淋巴瘤; NCT00520975: 乳腺癌; NCT00528567: 乳腺癌; NCT00545077: 乳腺癌; NCT00548548: 胃癌; NCT00567554: 乳腺癌; NCT00600340: 乳腺癌; NCT00625898: 乳腺癌; NCT00868634: 乳腺癌; NCT00887822: 胃癌; NCT00929240: 乳腺癌;  NCT01093235: 乳腺癌; NCT01200212: 乳腺癌; NCT01214720: 胰腺癌; NCT01236560: 脑癌，星形细胞瘤; NCT01250379: 乳腺癌; NCT01303679: 乳腺癌; NCT03434379: 肝癌	是	否	敏感性增加;可能发生胃肠道穿孔和出血	肺癌; 腹膜癌; 宫颈癌; 胶质母细胞瘤; 结直肠癌; 卵巢癌; 肾癌; 输卵管癌	II
Avastin	Avastin;bevacizumab(贝伐单抗) 	VEGF	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT00507585:Phase 1:Completed:No publish;ASCO 2016 (abstr 11053)	NCT00028990: 乳腺癌; NCT00088894: 胰腺癌; NCT00109239: 乳腺癌; NCT00110214: 前列腺癌; NCT00262067: 乳腺癌; NCT00281697: 乳腺癌;NCT00324987: 胃肠道间质瘤; NCT00333775: 乳腺癌; NCT00373256: 乳腺癌; NCT00391092: 乳腺癌; NCT00448591: 乳腺癌; NCT00450203: 胃癌; NCT00486759: 淋巴瘤; NCT00520975: 乳腺癌; NCT00528567: 乳腺癌; NCT00545077: 乳腺癌; NCT00548548: 胃癌; NCT00567554: 乳腺癌; NCT00600340: 乳腺癌; NCT00625898: 乳腺癌; NCT00868634: 乳腺癌; NCT00887822: 胃癌; NCT00929240: 乳腺癌;  NCT01093235: 乳腺癌; NCT01200212: 乳腺癌; NCT01214720: 胰腺癌; NCT01236560: 脑癌，星形细胞瘤; NCT01250379: 乳腺癌; NCT01303679: 乳腺癌; NCT03434379: 肝癌	是	否	敏感性降低;可能发生胃肠道穿孔和出血	肺癌; 腹膜癌; 宫颈癌; 胶质母细胞瘤; 结直肠癌; 卵巢癌; 肾癌; 输卵管癌	II
Avastin	Avastin;bevacizumab(贝伐单抗) 	VEGF	NF2:del	NF2	NF2 deletion	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	NCT00507585:Phase 1:Completed:No publish;PMID: 19587327, 22805104, 26022982	NCT00028990: 乳腺癌; NCT00088894: 胰腺癌; NCT00109239: 乳腺癌; NCT00110214: 前列腺癌; NCT00262067: 乳腺癌; NCT00281697: 乳腺癌;NCT00324987: 胃肠道间质瘤; NCT00333775: 乳腺癌; NCT00373256: 乳腺癌; NCT00391092: 乳腺癌; NCT00448591: 乳腺癌; NCT00450203: 胃癌; NCT00486759: 淋巴瘤; NCT00520975: 乳腺癌; NCT00528567: 乳腺癌; NCT00545077: 乳腺癌; NCT00548548: 胃癌; NCT00567554: 乳腺癌; NCT00600340: 乳腺癌; NCT00625898: 乳腺癌; NCT00868634: 乳腺癌; NCT00887822: 胃癌; NCT00929240: 乳腺癌;  NCT01093235: 乳腺癌; NCT01200212: 乳腺癌; NCT01214720: 胰腺癌; NCT01236560: 脑癌，星形细胞瘤; NCT01250379: 乳腺癌; NCT01303679: 乳腺癌; NCT03434379: 肝癌	是	否	敏感性增加;可能发生胃肠道穿孔和出血	肺癌; 腹膜癌; 宫颈癌; 胶质母细胞瘤; 结直肠癌; 卵巢癌; 肾癌; 输卵管癌	II
Avastin	Avastin;bevacizumab(贝伐单抗) 	VEGF	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT00507585:Phase 1:Completed:No publish;PMID: 24232489, 2485933	NCT00028990: 乳腺癌; NCT00088894: 胰腺癌; NCT00109239: 乳腺癌; NCT00110214: 前列腺癌; NCT00262067: 乳腺癌; NCT00281697: 乳腺癌;NCT00324987: 胃肠道间质瘤; NCT00333775: 乳腺癌; NCT00373256: 乳腺癌; NCT00391092: 乳腺癌; NCT00448591: 乳腺癌; NCT00450203: 胃癌; NCT00486759: 淋巴瘤; NCT00520975: 乳腺癌; NCT00528567: 乳腺癌; NCT00545077: 乳腺癌; NCT00548548: 胃癌; NCT00567554: 乳腺癌; NCT00600340: 乳腺癌; NCT00625898: 乳腺癌; NCT00868634: 乳腺癌; NCT00887822: 胃癌; NCT00929240: 乳腺癌;  NCT01093235: 乳腺癌; NCT01200212: 乳腺癌; NCT01214720: 胰腺癌; NCT01236560: 脑癌，星形细胞瘤; NCT01250379: 乳腺癌; NCT01303679: 乳腺癌; NCT03434379: 肝癌	是	否	敏感性增加;可能发生胃肠道穿孔和出血	肺癌; 腹膜癌; 宫颈癌; 胶质母细胞瘤; 结直肠癌; 卵巢癌; 肾癌; 输卵管癌	II
Avastin	Avastin;bevacizumab(贝伐单抗) 	VEGF	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT00507585:Phase 1:Completed:No publish;ASCO 2016 (abstr 11053)	NCT00028990: 乳腺癌; NCT00088894: 胰腺癌; NCT00109239: 乳腺癌; NCT00110214: 前列腺癌; NCT00262067: 乳腺癌; NCT00281697: 乳腺癌;NCT00324987: 胃肠道间质瘤; NCT00333775: 乳腺癌; NCT00373256: 乳腺癌; NCT00391092: 乳腺癌; NCT00448591: 乳腺癌; NCT00450203: 胃癌; NCT00486759: 淋巴瘤; NCT00520975: 乳腺癌; NCT00528567: 乳腺癌; NCT00545077: 乳腺癌; NCT00548548: 胃癌; NCT00567554: 乳腺癌; NCT00600340: 乳腺癌; NCT00625898: 乳腺癌; NCT00868634: 乳腺癌; NCT00887822: 胃癌; NCT00929240: 乳腺癌;  NCT01093235: 乳腺癌; NCT01200212: 乳腺癌; NCT01214720: 胰腺癌; NCT01236560: 脑癌，星形细胞瘤; NCT01250379: 乳腺癌; NCT01303679: 乳腺癌; NCT03434379: 肝癌	是	否	敏感性降低;可能发生胃肠道穿孔和出血	肺癌; 腹膜癌; 宫颈癌; 胶质母细胞瘤; 结直肠癌; 卵巢癌; 肾癌; 输卵管癌	II
Avastin	Avastin;bevacizumab(贝伐单抗) 	VEGF	NF2:.	NF2	NF2 oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	NCT00507585:Phase 1:Completed:No publish;PMID: 19587327, 22805104, 26022982	NCT00028990: 乳腺癌; NCT00088894: 胰腺癌; NCT00109239: 乳腺癌; NCT00110214: 前列腺癌; NCT00262067: 乳腺癌; NCT00281697: 乳腺癌;NCT00324987: 胃肠道间质瘤; NCT00333775: 乳腺癌; NCT00373256: 乳腺癌; NCT00391092: 乳腺癌; NCT00448591: 乳腺癌; NCT00450203: 胃癌; NCT00486759: 淋巴瘤; NCT00520975: 乳腺癌; NCT00528567: 乳腺癌; NCT00545077: 乳腺癌; NCT00548548: 胃癌; NCT00567554: 乳腺癌; NCT00600340: 乳腺癌; NCT00625898: 乳腺癌; NCT00868634: 乳腺癌; NCT00887822: 胃癌; NCT00929240: 乳腺癌;  NCT01093235: 乳腺癌; NCT01200212: 乳腺癌; NCT01214720: 胰腺癌; NCT01236560: 脑癌，星形细胞瘤; NCT01250379: 乳腺癌; NCT01303679: 乳腺癌; NCT03434379: 肝癌	是	否	敏感性增加;可能发生胃肠道穿孔和出血	肺癌; 腹膜癌; 宫颈癌; 胶质母细胞瘤; 结直肠癌; 卵巢癌; 肾癌; 输卵管癌	II
Avastin	Avastin;bevacizumab(贝伐单抗) 	VEGF	VHL:.	VHL	VHL oncogenic mutation	3:10183481..10183881..exon1,10188187..10188330..exon2,10191460..10191699..exon3	NCT00507585:Phase 1:Completed:No publish;PMID: 18635227	NCT00028990: 乳腺癌; NCT00088894: 胰腺癌; NCT00109239: 乳腺癌; NCT00110214: 前列腺癌; NCT00262067: 乳腺癌; NCT00281697: 乳腺癌;NCT00324987: 胃肠道间质瘤; NCT00333775: 乳腺癌; NCT00373256: 乳腺癌; NCT00391092: 乳腺癌; NCT00448591: 乳腺癌; NCT00450203: 胃癌; NCT00486759: 淋巴瘤; NCT00520975: 乳腺癌; NCT00528567: 乳腺癌; NCT00545077: 乳腺癌; NCT00548548: 胃癌; NCT00567554: 乳腺癌; NCT00600340: 乳腺癌; NCT00625898: 乳腺癌; NCT00868634: 乳腺癌; NCT00887822: 胃癌; NCT00929240: 乳腺癌;  NCT01093235: 乳腺癌; NCT01200212: 乳腺癌; NCT01214720: 胰腺癌; NCT01236560: 脑癌，星形细胞瘤; NCT01250379: 乳腺癌; NCT01303679: 乳腺癌; NCT03434379: 肝癌	是	否	敏感性增加;可能发生胃肠道穿孔和出血	肺癌; 腹膜癌; 宫颈癌; 胶质母细胞瘤; 结直肠癌; 卵巢癌; 肾癌; 输卵管癌	II
Avelumab	Avelumab (MSB0010718C)	PD-L1	CD274 overexpression	CD274	CD274 overexpression	9:5456063..5456175..exon1,5457068..5457430..exon2,5462823..5463131..exon3,5462823..5463227..exon4,5465488..5465616..exon5,5466759..5466839..exon6,5467829..5467912..exon7	NCT03289533:Phase 1:Recruiting:No publish||NCT03389126:Phase 2:Recruiting:No publish	.	是（非本癌种）	否	敏感性增加	默克细胞癌（MCC）	II
AZD-0530	AZD-0530;Saracatinib（塞卡替尼）	CYP3A	.	CYP3A4	CYP3A4	7:99355705..99355861..exon1,99358431..99358614..exon2,99359653..99359900..exon3,99361467..99361648..exon4,99363989..99364076..exon5,99364743..99364888..exon6,99364743..99364891..exon7,99365966..99366135..exon8,99367380..99367489..exon9,99367734..99367868..exon10,99370202..99370322..exon11,99375640..99375713..exon12,99377604..99377718..exon13,99381623..99381754..exon14	NCT00475956:Phase 1:Completed:No publish	.	是（非本癌种）	.	.	骨肉瘤，卵巢癌，输卵管癌，原发性腹膜癌。	III
AZD-8055	AZD-8055	mTOR	.	MTOR	MTOR	1:11167491..11167567..exon1,11168227..11168353..exon2,11169336..11169437..exon3,11169695..11169796..exon4,11172898..11172984..exon5,11174364..11174520..exon6,11174859..11174954..exon7,11175442..11175535..exon8,11177050..11177153..exon9,11181292..11181435..exon10,11182025..11182193..exon11,11184544..11184700..exon12,11186668..11186863..exon13,11187056..11187211..exon14,11187670..11187873..exon15,11188050..11188193..exon16,11188500..11188619..exon17,11188901..11189018..exon18,11189784..11189905..exon19,11190575..11190844..exon20,11193126..11193264..exon21,11194397..11194533..exon22,11199350..11199502..exon23,11199579..11199725..exon24,11204694..11204822..exon25,11205014..11205112..exon26,11206722..11206858..exon27,11210172..11210293..exon28,11217198..11217358..exon29,11227488..11227584..exon30,11259304..11259470..exon31,11259587..11259770..exon32,11264607..11264770..exon33,11269358..11269525..exon34,11270860..11270973..exon35,11272358..11272541..exon36,11272842..11272975..exon37,11273445..11273633..exon38,11276194..11276301..exon39,11288714..11288985..exon40,11290971..11291121..exon41,11291346..11291501..exon42,11292482..11292595..exon43,11293444..11293554..exon44,11294189..11294332..exon45,11297889..11298115..exon46,11298448..11298684..exon47,11300349..11300614..exon48,11301599..11301748..exon49,11303160..11303367..exon50,11307671..11307800..exon51,11307865..11308161..exon52,11313885..11314040..exon53,11316038..11316259..exon54,11316979..11317232..exon55,11318531..11318660..exon56,11319294..11319516..exon57	NCT00999882:Phase 1:Completed:No publish	.	否	否	.	淋巴瘤，实体瘤，恶性神经胶质瘤，脑干神经胶质瘤，等等	III
Bavituximab	Bavituximab	IgG3	.	.	.	.	NCT01264705:Phase 1|Phase 2:Unknown status:No publish||NCT03519997:Phase 2:Recruiting:No publish	.	否	否	.	肝癌;乳腺癌	III
BAY-869766	BAY-869766;Refametinib	MEK	.	.	.	.	NCT01204177:Phase 2:Completed:No publish	.	否	否	.	肝癌	III
BBI-503	BBI-503	.	.	.	.	.	NCT02279719:Phase 1|Phase 2:Recruiting:No publish||NCT02354898:Phase 1:Recruiting:No publish||NCT02232633:Phase 2:Active, not recruiting:No publish	.	否	否	.	肝癌等	III
BBI-608	BBI-608;napabucasin	.	.	.	.	.	NCT02279719:Phase 1|Phase 2:Recruiting:No publish||NCT02358395:Phase 1:Completed:No publish	.	否	否	.	肝癌;结直肠癌	III
Belinostat	Belinostat;PXD-101	.	.	.	.	.	NCT00321594:Phase 1|Phase 2:Completed:No publish	.	是（非本癌种）	否	.	乳腺癌;肝癌;淋巴瘤	III
BGB-A317	BGB-A317	PD-1	.	.	.	.	NCT03419897:Phase 2:Recruiting:No publish||NCT03412773:Phase 3:Recruiting:No publish	.	否	否	.	肝癌;实体瘤（国产研发）	II
BIBF-1120	Nintedanib	FGFR;RET; PDGFR; VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	RET__.	RET	RET fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	NCT01004003:Phase 2:Completed:No publish||NCT00987935:Phase 2:Completed:No publish	.	是（非本癌种）	否	敏感性增加	肺纤维化	III
BIIB022	BIIB022	IGF-1R	.	.	.	.	NCT00956436:Phase 1:Completed:No publish	.	否	否	.	肝癌	III
Binimetinib	Binimetinib;MEK-162	MEK;MAP3K1;MAP3K2	BRAF#p.V600E;BRAF#p.V600K	BRAF	p.V600E;p.V600K	7:140453136..140453137	NCT02465060:Phase 2:Recruiting:No publish	.	是（非本癌种）	否	敏感性增加	实体瘤;联合Encorafenib治疗不可切除或转移性黑色素瘤	II
BLU-554	BLU-554	FGFR4	.	FGFR4	FGFR4	5:176516553..176516704..exon1,176517380..176517664..exon2,176517735..176517836..exon3,176517928..176518115..exon4,176518675..176518819..exon5,176519311..176519522..exon6,176519636..176519795..exon7,176520128..176520188..exon8,176520128..176520342..exon9,176520322..176520562..exon10,176520396..176520512..exon11,176520396..176520562..exon12,176520644..176520786..exon13,176522320..176522451..exon14,176522523..176522734..exon15,176523047..176523190..exon16,176523277..176523368..exon17,176523594..176523752..exon18,176524282..176524408..exon19,176524517..176524727..exon20	NCT02508467:Phase 1:Recruiting:No publish	.	否	否	.	肝癌	III
BMS-247550	BMS-247550;Ixabepilone（依沙比酮） 	TUBB3	.	TUBB3	TUBB3	16:89989759..89989876..exon1,89998968..89999097..exon2,89999865..89999996..exon3,89999875..89999996..exon4,90001126..90002262..exon5	NCT00049400:Phase 1:Completed:Current version of study NCT00049400 on ClinicalTrials.gov	.	是（非本癌种）	否	.	不再对目前可用的化疗作出反应的侵袭性转移或局部晚期乳腺癌	III
Brivanib	Brivanib;BMS-582664	VEGFR2	.	VEGFR2(KDR)	KDR	4:55946057..55946340..exon1,55948112..55948218..exon2,55948692..55948812..exon3,55953763..55953935..exon4,55955024..55955150..exon5,55955530..55955650..exon6,55955847..55955979..exon7,55956112..55956255..exon8,55958773..55958891..exon9,55960958..55961132..exon10,55961733..55961842..exon11,55962385..55962519..exon12,55963818..55963943..exon13,55964293..55964449..exon14,55964853..55964980..exon15,55968053..55968205..exon16,55968518..55968685..exon17,55970799..55971161..exon18,55971988..55972117..exon19,55972843..55972987..exon20,55973893..55974070..exon21,55976559..55976743..exon22,55976810..55976945..exon23,55979460..55979658..exon24,55980282..55980442..exon25,55981030..55981219..exon26,55981437..55981588..exon27,55984760..55984977..exon28,55987253..55987367..exon29,55991383..55991510..exon30	NCT00825955:Phase 3:Completed:No publish||NCT00437424:Phase 1:Completed:No publish||NCT01540461:Phase 1:Completed:No publish||NCT00355238:Phase 2:Completed:No publish||NCT03516071:Phase 2:Recruiting:No publish||NCT03516071:Phase 2:Recruiting:No publish||NCT00908752:Phase 3:Completed:No publish||NCT00858871:Phase 3:Completed:No publish	.	否	否	.	肝癌;结直肠癌	III
C188-9	C188-9	STAT3	.	STAT3	STAT3	17:40467712..40467828..exon1,40468794..40468879..exon2,40468796..40468929..exon3,40469189..40469252..exon4,40474289..40474522..exon5,40474292..40474522..exon6,40475011..40475171..exon7,40475267..40475382..exon8,40475580..40475653..exon9,40476718..40476874..exon10,40476970..40477089..exon11,40478123..40478227..exon12,40481417..40481485..exon13,40481561..40481675..exon14,40481754..40481804..exon15,40483479..40483559..exon16,40485680..40485793..exon17,40485898..40486077..exon18,40489442..40489614..exon19,40489770..40489885..exon20,40490738..40490840..exon21,40491321..40491437..exon22,40497566..40497685..exon23,40498576..40498741..exon24,40500396..40500584..exon25	NCT03195699:Phase 1:Recruiting:No publish	.	否	否	.	肝癌	III
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	RET#p.C634W	RET	p.C634W	10:43609948..43609948	PMID: 21470995	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-63.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到10个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	ROS1#p.G2032R	ROS1	p.G2032R	6:117638346..117638346	PMID: 25351743	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-64.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到11个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	RET#p.M918T	RET	p.M918T	10:43617416..43617416	PMID: 21470995	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-65.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到12个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	ABL1#p.V299L	ABL1	p.V299L	9:133747590..133747590	PMID: 26924578	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-66.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到13个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	HGF:over	HGF	HGF overexpression	7:81331846..81332083..exon1,81334695..81334861..exon2,81334952..81335079..exon3,81335592..81335753..exon4,81336595..81336690..exon5,81339452..81339569..exon6,81340786..81340845..exon7,81346537..81346691..exon8,81350050..81350173..exon9,81355195..81355343..exon10,81358910..81359105..exon11,81372207..81372275..exon12,81372658..81372797..exon13,81374305..81374446..exon14,81381377..81381588..exon15,81381425..81381573..exon16,81381425..81381588..exon17,81386494..81386629..exon18,81387997..81388130..exon19,81392012..81392198..exon20,81399189..81399337..exon21	PMID: 25534569	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-67.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到14个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	MET:amp	MET	MET amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	ENA 2015 (abstr A52)	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-68.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到15个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	RET__.	RET	RET fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 28447912	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-69.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到16个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	RET__TPCN1	RET	RET-TPCN1 fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 21470995	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-70.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到17个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Cabozantinib	Cabozantinib (卡博替尼)	MET;KDR;RET	ROS1__.	ROS1	ROS1 fusion	6:117609604..117609975..exon1,117622126..117622310..exon2,117629946..117630101..exon3,117631233..117631454..exon4,117632172..117632290..exon5,117638295..117638445..exon6,117639340..117639425..exon7,117641020..117641203..exon8,117642411..117642567..exon9,117645484..117645588..exon10,117647376..117647587..exon11,117650481..117650619..exon12,117658324..117658513..exon13,117662287..117662484..exon14,117662552..117662805..exon15,117663552..117663717..exon16,117665212..117665435..exon17,117674142..117674342..exon18,117677781..117678088..exon19,117678956..117679182..exon20,117680961..117681184..exon21,117681494..117681578..exon22,117683755..117684038..exon23,117686212..117686377..exon24,117686733..117686914..exon25,117687228..117687463..exon26,117700211..117700332..exon27,117704469..117704681..exon28,117706835..117707034..exon29,117708041..117708172..exon30,117708932..117709207..exon31,117710502..117711019..exon32,117714376..117714494..exon33,117715314..117715519..exon34,117715768..117715911..exon35,117717340..117717437..exon36,117718067..117718289..exon37,117724291..117724450..exon38,117725432..117725601..exon39,117730734..117730815..exon40,117737410..117737490..exon41,117739614..117739679..exon42,117746686..117746869..exon43	PMID: 27370605	Abou-Alfa G.K, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379: 54-71.	是（非本癌种）	否	敏感性增加;《新英格兰医学杂志》最近发布的一项研究显示，使用卡博替尼（Cabozantinib）这种新型药物治疗晚期肝癌，可使患者死亡风险降低56%，存活寿命延长到18个月，卡博替尼+特异性好的靶向药”，可能是解决肝癌耐药的好搭配。	甲状腺癌; 肾癌	I
Capivasertib	Capivasertib;AZD-5363	.	.	.	.	.	NCT02465060:Phase 2:Recruiting:No publish	.	否	否	.	转移性乳腺癌;肝癌	III
CBT-501	CBT-501;genolimzumab	PD-1	.	.	.	.	NCT03053466:Phase 1:Recruiting:No publish	.	否	否	.	肝癌	III
CDX-1140	CDX-1140	IgG2;CD40	.	CD40	CD40	20:44746932..44747043..exon1,44750448..44750547..exon2,44750861..44751007..exon3,44751238..44751405..exon4,44751754..44751868..exon5,44755268..44755350..exon6,44755268..44755390..exon7,44756766..44756873..exon8,44756766..44756885..exon9,44756958..44757007..exon10,44756958..44757046..exon11,44757510..44757729..exon12	NCT03329950:Phase 1:Recruiting:No publish	.	否	否	.	肝癌	III
Cediranib	Cediranib	VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT00238394:Phase 2:Completed:No publish	.	否	否	敏感性降低	肝癌;神经纤维瘤	III
Cediranib	Cediranib	VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT00238394:Phase 2:Completed:No publish	.	否	否	敏感性降低	肝癌;神经纤维瘤	III
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	KRAS#p.G13D	KRAS	p.G13D	12:25398281..25398281	PMID: 27114605;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	敏感性降低;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	KRAS#p.G13D	KRAS	p.G13D	12:25398281..25398281	PMID: 27114605;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.G465R	EGFR	p.G465R	7:55227926..55227926	PMID: 22270724, 26059438, 25623215, 22270724, 26888827;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.G465R	EGFR	p.G465R	7:55227926..55227926	PMID: 25623215;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.I491M	EGFR	p.I491M	7:55228006..55228006	PMID: 25623215;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.K467T	EGFR	p.K467T	7:55227932..55227932	PMID: 22270724, 26059438, 25623215, 22270724, 26888827;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.P546S	EGFR	p.P546S	7:55231430..55231430	PMID: 23578570;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	敏感性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	PTEN#p.R159S	PTEN	p.R159S	10:89692993..89692993	PMID: 21163703;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	敏感性降低;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	PTEN#p.R233*	PTEN	p.R233*	10:89717672..89717672	PMID: 21163703;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	敏感性降低;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.R451C	EGFR	p.R451C	7:55227885..55227885	PMID: 22270724, 26059438, 25623215, 22270724, 26888827;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.S464L	EGFR	p.S464L	7:55227923..55227924	PMID: 25623215;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR#p.S492R	EGFR	p.S492R	7:55228009..55228009	PMID: 22270724, 26059438, 25623215, 22270724, 26888827;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 20619739, 21163703, 23325582;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR::consequence::inframe_insertion:729-761	EGFR	EGFR exon 19 insertions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	ESMO 2012 (abstr 1289);NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	敏感性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	NF2:del;EGFR:.	EGFR	NF2 deletion + EGFR oncogenic mutation	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 24813888;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	NF2:del;EGFR:.	NF2	NF2 deletion + EGFR oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 24813888;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	BRAF:V600.	BRAF	BRAF p.V600	7:140453136..140453136	PMID: 27729313;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	敏感性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	EGFR:over	EGFR	EGFR overexpression	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	敏感性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	NF2:.;EGFR:.	EGFR	NF2 oncogenic mutation + EGFR oncogenic mutation	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 24813888;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	NF2:.;EGFR:.	NF2	NF2 oncogenic mutation + EGFR oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 24813888;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	NRAS:.	NRAS	NRAS oncogenic mutation	1:115251105..115251285..exon1,115252179..115252359..exon2,115256410..115256609..exon3,115258660..115258831..exon4	PMID: 24024839, 20619739, 23325582;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	NRAS:wild-type	NRAS	NRAS oncogenic mutation	1:115251105..115251285..exon1,115252179..115252359..exon2,115256410..115256609..exon3,115258660..115258831..exon4	;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	PIK3CA:.	PIK3CA	PIK3CA oncogenic mutation	3:178916563..178916975..exon1,178917467..178917697..exon2,178919067..178919338..exon3,178921321..178921587..exon4,178922280..178922386..exon5,178927372..178927498..exon6,178927963..178928136..exon7,178928208..178928363..exon8,178935987..178936132..exon9,178936973..178937075..exon10,178937348..178937533..exon11,178937726..178937850..exon12,178938763..178938955..exon13,178941858..178941985..exon14,178942477..178942619..exon15,178943739..178943838..exon16,178947049..178947240..exon17,178947781..178947919..exon18,178948002..178948174..exon19,178951871..178952202..exon20	PMID: 19223544, 20619739;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cetuximab	Cetuximab (西妥昔单抗)	EGFR	PTEN:.	PTEN	PTEN biallelic inactivation	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	Caris molecular intelligence;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	NCT00075686: 胰腺癌; NCT00095199: 非小细胞肺癌; NCT00112294: 非小细胞肺癌; NCT00148798: 非小细胞肺癌; NCT00509561: 食管癌; NCT00820755: 非小细胞肺癌; NCT02438722: 非小细胞肺癌;NCT00980239:Phase 1:Completed:No publish||NCT01564810:Phase 4:Unknown status:No publish||NCT00397384:Phase 1:Completed:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT00153998:Phase 2:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish||NCT03319459:Phase 1:Recruiting:No publish||NCT00142428:Phase 2:Completed:No publish||NCT01836653:Phase 2:Completed:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	是（非本癌种）	是（非本癌种）	耐药性增加;较少数联合Erbitux和放射治疗的头颈癌患者，以及较少数联合5-FU治疗的患者发生心脏骤停/猝死；此外，该药物并未指示用于RAS突变的结直肠癌患者	结直肠癌; 头颈癌	II
Cobimetinib	Cobimetinib (卡比替尼)	MAP2K1;MEK1	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	NCT03340558:Phase 2:Not yet recruiting:No publish	.	是（非本癌种）	否	敏感性增加;部分患者具有严重的光敏感，建议避免长时间阳光照射；具有胎儿毒性，建议具有生殖能力的女性进行有效保护。	黑色素瘤	II
Cobimetinib	Cobimetinib (卡比替尼)	MAP2K1;MEK1	BRAF#p.V600K	BRAF	p.V600K	7:140453136..140453137	NCT03340558:Phase 2:Not yet recruiting:No publish	.	是（非本癌种）	否	敏感性增加部分患者具有严重的光敏感，建议避免长时间阳光照射；具有胎儿毒性，建议具有生殖能力的女性进行有效保护。	黑色素瘤	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.A348D	ALK	p.A348D	2:29754891..29754891	PMID: 26032424	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.C1156Y	ALK	p.C1156Y	2:29445258..29445258	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.C1156Y	ALK	p.C1156Y	2:29445258..29445258	PMID: 20979473	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.C1156Y	ALK	p.C1156Y	2:29445258..29445258	PMID: 23434628	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.F1174L	ALK	p.F1174L	2:29443695..29443695	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.F1174L	ALK	p.F1174L	2:29443695..29443695	PMID: 22072639	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.F1245C	ALK	p.F1245C	2:29436859..29436859	PMID: 22072639	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.F856S	ALK	p.F856S	2:29455234..29455234	PMID: 26032424	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.G1128A	ALK	p.G1128A	2:29445450..29445450	PMID: 22072639	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.G1202R	ALK	p.G1202R	2:29443613..29443613	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.G1269A	ALK	p.G1269A	2:29432682..29432682	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.G1269A	ALK	p.G1269A	2:29432682..29432682	PMID: 23344087	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.G1269A	ALK	p.G1269A	2:29432682..29432682	PMID: 23434628	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.G1269A	ALK	p.G1269A	2:29432682..29432682	PMID: 24675041	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ROS1#p.G2032R	ROS1	p.G2032R	6:117638346..117638346	PMID: 23724914, 25688157	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET#p.H1112L	MET	p.H1112L	7:116417464..116417464	AACR 2012 (abstr 1786)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET#p.H1112R	MET	p.H1112R	7:116417464..116417464	PMID: 17483355	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.I1171N	ALK	p.I1171N	2:29445213..29445213	PMID: 22072639	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.I1171T	ALK	p.I1171T	2:29445213..29445213	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.L1152R	ALK	p.L1152R	2:29445270..29445270	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.L1196M	ALK	p.L1196M	2:29443631..29443631	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.L1196M	ALK	p.L1196M	2:29443631..29443631	PMID: 20979473	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.L1196M	ALK	p.L1196M	2:29443631..29443631	PMID: 23434628	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.L1198F	ALK	p.L1198F	2:29443625..29443625	PMID: 26698910	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET#p.M1268T	MET	p.M1268T	7:116423474..116423474	PMID: 17483355	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.R1192P	ALK	p.R1192P	2:29443655..294436355	PMID: 22072639	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.R1275Q	ALK	p.R1275Q	2:29432664..29432664	PMID: 22072639	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET#p.R988C	MET	p.R988C	7:116411923..116411923	PMID: 17483355	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.S1206Y	ALK	p.S1206Y	2:29443600..29443600	PMID: 22277784, 25228534	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK#p.S1206Y	ALK	p.S1206Y	2:29443600..29443600	PMID: 24675041	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET#p.T1010I	MET	p.T1010I	7:116411990..116411990	PMID: 17483355	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET#p.V1110I	MET	p.V1110I	7:116417457..116417457	PMID: 17483355	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ABL1#p.V299L	ABL1	p.V299L	9:133747590..133747590	PMID: 26924578	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK::consequence::inframe_insertion:.1151T.	ALK	ALK inframe insertion (1151T)	2:29416039..29416798..exon1,29419625..29419736..exon2,29420397..29420552..exon3,29430026..29430148..exon4,29432641..29432754..exon5,29436839..29436957..exon6,29443561..29443711..exon7,29445199..29445284..exon8,29445372..29445483..exon9,29446197..29446404..exon10,29448316..29448441..exon11,29449777..29449950..exon12,29450429..29450548..exon13,29451739..29451942..exon14,29455159..29455324..exon15,29456420..29456572..exon16,29462535..29462706..exon17,29473960..29474143..exon18,29497954..29498103..exon19,29498257..29498372..exon20,29519743..29519933..exon21,29541159..29541280..exon22,29543606..29543758..exon23,29551205..29551357..exon24,29606587..29606735..exon25,29754770..29754992..exon26,29917705..29917890..exon27,29940433..29940573..exon28,30142848..30143575..exon29	PMID: 22277784	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK:amp	ALK	ALK amplification	2:29416039..29416798..exon1,29419625..29419736..exon2,29420397..29420552..exon3,29430026..29430148..exon4,29432641..29432754..exon5,29436839..29436957..exon6,29443561..29443711..exon7,29445199..29445284..exon8,29445372..29445483..exon9,29446197..29446404..exon10,29448316..29448441..exon11,29449777..29449950..exon12,29450429..29450548..exon13,29451739..29451942..exon14,29455159..29455324..exon15,29456420..29456572..exon16,29462535..29462706..exon17,29473960..29474143..exon18,29497954..29498103..exon19,29498257..29498372..exon20,29519743..29519933..exon21,29541159..29541280..exon22,29543606..29543758..exon23,29551205..29551357..exon24,29606587..29606735..exon25,29754770..29754992..exon26,29917705..29917890..exon27,29940433..29940573..exon28,30142848..30143575..exon29	PMID: 22277784	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK:amp	ALK	ALK amplification	2:29416039..29416798..exon1,29419625..29419736..exon2,29420397..29420552..exon3,29430026..29430148..exon4,29432641..29432754..exon5,29436839..29436957..exon6,29443561..29443711..exon7,29445199..29445284..exon8,29445372..29445483..exon9,29446197..29446404..exon10,29448316..29448441..exon11,29449777..29449950..exon12,29450429..29450548..exon13,29451739..29451942..exon14,29455159..29455324..exon15,29456420..29456572..exon16,29462535..29462706..exon17,29473960..29474143..exon18,29497954..29498103..exon19,29498257..29498372..exon20,29519743..29519933..exon21,29541159..29541280..exon22,29543606..29543758..exon23,29551205..29551357..exon24,29606587..29606735..exon25,29754770..29754992..exon26,29917705..29917890..exon27,29940433..29940573..exon28,30142848..30143575..exon29	PMID: 22235099	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK__.	ALK	ALK fusion	2:29416039..29416798..exon1,29419625..29419736..exon2,29420397..29420552..exon3,29430026..29430148..exon4,29432641..29432754..exon5,29436839..29436957..exon6,29443561..29443711..exon7,29445199..29445284..exon8,29445372..29445483..exon9,29446197..29446404..exon10,29448316..29448441..exon11,29449777..29449950..exon12,29450429..29450548..exon13,29451739..29451942..exon14,29455159..29455324..exon15,29456420..29456572..exon16,29462535..29462706..exon17,29473960..29474143..exon18,29497954..29498103..exon19,29498257..29498372..exon20,29519743..29519933..exon21,29541159..29541280..exon22,29543606..29543758..exon23,29551205..29551357..exon24,29606587..29606735..exon25,29754770..29754992..exon26,29917705..29917890..exon27,29940433..29940573..exon28,30142848..30143575..exon29	PMID: 24491302;NCT02270034	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK__.	ALK	ALK fusion	2:29416039..29416798..exon1,29419625..29419736..exon2,29420397..29420552..exon3,29430026..29430148..exon4,29432641..29432754..exon5,29436839..29436957..exon6,29443561..29443711..exon7,29445199..29445284..exon8,29445372..29445483..exon9,29446197..29446404..exon10,29448316..29448441..exon11,29449777..29449950..exon12,29450429..29450548..exon13,29451739..29451942..exon14,29455159..29455324..exon15,29456420..29456572..exon16,29462535..29462706..exon17,29473960..29474143..exon18,29497954..29498103..exon19,29498257..29498372..exon20,29519743..29519933..exon21,29541159..29541280..exon22,29543606..29543758..exon23,29551205..29551357..exon24,29606587..29606735..exon25,29754770..29754992..exon26,29917705..29917890..exon27,29940433..29940573..exon28,30142848..30143575..exon29	PMID: 20979472, 24687827	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK__.	ALK	ALK fusion	2:29416039..29416798..exon1,29419625..29419736..exon2,29420397..29420552..exon3,29430026..29430148..exon4,29432641..29432754..exon5,29436839..29436957..exon6,29443561..29443711..exon7,29445199..29445284..exon8,29445372..29445483..exon9,29446197..29446404..exon10,29448316..29448441..exon11,29449777..29449950..exon12,29450429..29450548..exon13,29451739..29451942..exon14,29455159..29455324..exon15,29456420..29456572..exon16,29462535..29462706..exon17,29473960..29474143..exon18,29497954..29498103..exon19,29498257..29498372..exon20,29519743..29519933..exon21,29541159..29541280..exon22,29543606..29543758..exon23,29551205..29551357..exon24,29606587..29606735..exon25,29754770..29754992..exon26,29917705..29917890..exon27,29940433..29940573..exon28,30142848..30143575..exon29	NCT02465060:Phase 2:Recruiting:No publish	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ALK:.	ALK	ALK oncogenic mutation	2:29416039..29416798..exon1,29419625..29419736..exon2,29420397..29420552..exon3,29430026..29430148..exon4,29432641..29432754..exon5,29436839..29436957..exon6,29443561..29443711..exon7,29445199..29445284..exon8,29445372..29445483..exon9,29446197..29446404..exon10,29448316..29448441..exon11,29449777..29449950..exon12,29450429..29450548..exon13,29451739..29451942..exon14,29455159..29455324..exon15,29456420..29456572..exon16,29462535..29462706..exon17,29473960..29474143..exon18,29497954..29498103..exon19,29498257..29498372..exon20,29519743..29519933..exon21,29541159..29541280..exon22,29543606..29543758..exon23,29551205..29551357..exon24,29606587..29606735..exon25,29754770..29754992..exon26,29917705..29917890..exon27,29940433..29940573..exon28,30142848..30143575..exon29	PMID: 22235099	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:Y1230C;Y1235D	MET	MET (Y1230C;Y1235D)	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 17483355	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:amp	MET	MET amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	NCT02499614;ASCO 2015 (abstr 2595)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:amp	MET	MET amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:amp	MET	MET amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 22162573	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:amp;BRAF:V600E	MET	MET amplification + BRAF (V600E)	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 27325282	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:amp;BRAF:V600E	BRAF	MET amplification + BRAF (V600E)	7:140434346..140434580..exon1,140439601..140439756..exon2,140449076..140449228..exon3,140453064..140453203..exon4,140453976..140454043..exon5,140476701..140476898..exon6,140477780..140477885..exon7,140481365..140481503..exon8,140482810..140482967..exon9,140487337..140487394..exon10,140494097..140494277..exon11,140500151..140500291..exon12,140501201..140501370..exon13,140507749..140507872..exon14,140508681..140508805..exon15,140534398..140534682..exon16,140549900..140550022..exon17,140624355..140624553..exon18	PMID: 27325282	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:amp;ERBB2:amp	ERBB2	MET amplification + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26432108	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:amp;ERBB2:amp	MET	MET amplification + ERBB2 amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 26432108	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET__.	MET	MET fusion	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 27748748	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	MET:1132-1330	MET	MET mutation in exon 16-19	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	AACR 2016 (abstr CT2006)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	NTRK1__.	NTRK1	NTRK1 fusion	1:156785571..156785640..exon1,156811862..156811995..exon2,156830676..156830948..exon3,156834135..156834230..exon4,156834509..156834601..exon5,156836691..156836780..exon6,156837885..156838051..exon7,156838286..156838449..exon8,156841404..156841557..exon9,156843414..156843761..exon10,156844164..156844202..exon11,156844352..156844428..exon12,156844687..156844810..exon13,156845301..156845468..exon14,156845861..156846012..exon15,156846181..156846374..exon16,156848903..156849164..exon17,156849780..156849959..exon18,156851238..156851484..exon19	ASCO 2013 (abstr 8023)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ROS1__.	ROS1	ROS1 fusion	6:117609604..117609975..exon1,117622126..117622310..exon2,117629946..117630101..exon3,117631233..117631454..exon4,117632172..117632290..exon5,117638295..117638445..exon6,117639340..117639425..exon7,117641020..117641203..exon8,117642411..117642567..exon9,117645484..117645588..exon10,117647376..117647587..exon11,117650481..117650619..exon12,117658324..117658513..exon13,117662287..117662484..exon14,117662552..117662805..exon15,117663552..117663717..exon16,117665212..117665435..exon17,117674142..117674342..exon18,117677781..117678088..exon19,117678956..117679182..exon20,117680961..117681184..exon21,117681494..117681578..exon22,117683755..117684038..exon23,117686212..117686377..exon24,117686733..117686914..exon25,117687228..117687463..exon26,117700211..117700332..exon27,117704469..117704681..exon28,117706835..117707034..exon29,117708041..117708172..exon30,117708932..117709207..exon31,117710502..117711019..exon32,117714376..117714494..exon33,117715314..117715519..exon34,117715768..117715911..exon35,117717340..117717437..exon36,117718067..117718289..exon37,117724291..117724450..exon38,117725432..117725601..exon39,117730734..117730815..exon40,117737410..117737490..exon41,117739614..117739679..exon42,117746686..117746869..exon43	NCT02465060:Phase 2:Recruiting:No publish	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ROS1__.	ROS1	ROS1 fusion	6:117609604..117609975..exon1,117622126..117622310..exon2,117629946..117630101..exon3,117631233..117631454..exon4,117632172..117632290..exon5,117638295..117638445..exon6,117639340..117639425..exon7,117641020..117641203..exon8,117642411..117642567..exon9,117645484..117645588..exon10,117647376..117647587..exon11,117650481..117650619..exon12,117658324..117658513..exon13,117662287..117662484..exon14,117662552..117662805..exon15,117663552..117663717..exon16,117665212..117665435..exon17,117674142..117674342..exon18,117677781..117678088..exon19,117678956..117679182..exon20,117680961..117681184..exon21,117681494..117681578..exon22,117683755..117684038..exon23,117686212..117686377..exon24,117686733..117686914..exon25,117687228..117687463..exon26,117700211..117700332..exon27,117704469..117704681..exon28,117706835..117707034..exon29,117708041..117708172..exon30,117708932..117709207..exon31,117710502..117711019..exon32,117714376..117714494..exon33,117715314..117715519..exon34,117715768..117715911..exon35,117717340..117717437..exon36,117718067..117718289..exon37,117724291..117724450..exon38,117725432..117725601..exon39,117730734..117730815..exon40,117737410..117737490..exon41,117739614..117739679..exon42,117746686..117746869..exon43	PMID: 24875859	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Crizotinib	Crizotinib (克唑替尼)	ALK 	ROS1__.	ROS1	ROS1 fusion	6:117609604..117609975..exon1,117622126..117622310..exon2,117629946..117630101..exon3,117631233..117631454..exon4,117632172..117632290..exon5,117638295..117638445..exon6,117639340..117639425..exon7,117641020..117641203..exon8,117642411..117642567..exon9,117645484..117645588..exon10,117647376..117647587..exon11,117650481..117650619..exon12,117658324..117658513..exon13,117662287..117662484..exon14,117662552..117662805..exon15,117663552..117663717..exon16,117665212..117665435..exon17,117674142..117674342..exon18,117677781..117678088..exon19,117678956..117679182..exon20,117680961..117681184..exon21,117681494..117681578..exon22,117683755..117684038..exon23,117686212..117686377..exon24,117686733..117686914..exon25,117687228..117687463..exon26,117700211..117700332..exon27,117704469..117704681..exon28,117706835..117707034..exon29,117708041..117708172..exon30,117708932..117709207..exon31,117710502..117711019..exon32,117714376..117714494..exon33,117715314..117715519..exon34,117715768..117715911..exon35,117717340..117717437..exon36,117718067..117718289..exon37,117724291..117724450..exon38,117725432..117725601..exon39,117730734..117730815..exon40,117737410..117737490..exon41,117739614..117739679..exon42,117746686..117746869..exon43	PMID: 25264305	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	适用于ALK阳性和ROS1阳性的非小细胞肺癌患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K2#p.C125S	MAP2K2	p.C125S	19:4110583..4110583	PMID: 24265153; PMID: 25452114	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	AKT1#p.E17K	AKT1	p.E17K	14:105246551..105246551	PMID: 24265152	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K2#p.E207K	MAP2K2	p.E207K	19:4101103..4101103	PMID: 25452114	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	PIK3CA#p.E545*	PIK3CA	p.E545*	3:178936091..178936091	PMID: 24265155	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K1#p.G128D	MAP2K1	p.G128D	15:66729175..66729175	PMID: 25452114	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	NRAS#p.G12D	NRAS	p.G12D	1:115258747..115258747	PMID: 24265153; PMID: 25452114	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K1#p.K57E	MAP2K1	p.K57E	15:66727453..66727453	PMID: 24463458	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K2#p.L46F	MAP2K2	p.L46F	19:4117584..4117584	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K2#p.N126D	MAP2K2	p.N126D	19:4110581..4110581	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K1#p.P124S	MAP2K1	p.P124S	15:66729162..66729162	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K2#p.Q60P	MAP2K2	p.Q60P	19:4117541..4117541	PMID: 24265154; PMID: 25705882	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	NRAS#p.Q61K	NRAS	p.Q61K	1:115256530..115256530	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	AKT1#p.Q79K	AKT1	p.Q79K	14:105243048..105243048	PMID: 24265152	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	G6PD#p.S218F	G6PD	p.S218F	X:153762634..153762634	FDA	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	毒性增加 (Haemolytic Anemia)	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	MAP2K2#p.V35M	MAP2K2	p.V35M	19:4117617..4117617	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 23470635, 22608338	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 23470635, 22608338	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 23524406, 22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR), 20818844, 23489023, 27080216	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	FDA	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	NCCN	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	BRAF#p.V600R	BRAF	p.V600R	7:140453136..140453137	PMID: 23237741	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	BRAF:V600.	BRAF	BRAF p.V600	7:140453136..140453137	ENA 2014 (abstr 11LBA)	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	G6PD:V98M;G6PD:N156D	G6PD	G6PD p.V98M + G6PD (N156D)	X:153764217..153763492	FDA	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	毒性增加 (Haemolytic Anemia)	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dabrafenib	Dabrafenib (达拉非尼)	BRAF;MAP2K2;RAF1;SIK1;NEK11	G6PD:.	G6PD	G6PD biallelic inactivation	X:153760164..153760315..exon1,153760392..153760505..exon2,153760590..153760687..exon3,153760771..153761027..exon4,153761146..153761353..exon5,153761780..153761894..exon6,153762239..153762385..exon7,153762542..153762721..exon8,153763372..153763610..exon9,153764141..153764270..exon10,153764345..153764403..exon11,153774240..153774388..exon12,153774240..153774420..exon13,153774993..153775135..exon14	FDA	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	毒性增加 (Haemolytic Anemia)	药物批准适用于BRAF V600突变或V600K突变的黑色素瘤患者；药物具有胚胎毒性，使用期间注意避免	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	CBL#p.C384R	CBL	p.C384R	11:119148930..119148930	PMID: 23696637	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.D400Y	ABL1	p.D400Y	9:133750310..133750310	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.D444Y	ABL1	p.D444Y	9:133753861..133753861	PMID: 20673586	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT#p.D816F	KIT	p.D816F	4:55599320..55599321	PMID: 16397263	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT#p.D816V	KIT	p.D816V	4:55599321..55599321	PMID: 18986703	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT#p.D816V	KIT	p.D816V	4:55599321..55599321	PMID: 18559612	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT#p.D816V	KIT	p.D816V	4:55599321..55599321	PMID: 16397263	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT#p.D816Y	KIT	p.D816Y	4:55599320..55599320	PMID: 16397263	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 18794084	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21931113	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21156844	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 19260121; PMID: 20673586	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317C	ABL1	p.F317C	9:133748289..133748289	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317I	ABL1	p.F317I	9:133748288..133748288	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 19156415	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21357704	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 22873741	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21156844	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21264552	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317R	ABL1	p.F317R	9:133748288..133748289	PMID: 23044928	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F317V	ABL1	p.F317V	9:133748288..133748288	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 19260121	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 26308885	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.F401L	ABL1	p.F401L	9:133750313..133750313	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	BTK#p.FG540LC	BTK	p.FG540LC	9:100609628..100609629	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21264552	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.G253C	DDR2	p.G253C	1:162729671..162729671	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	EPHA2#p.G391R	EPHA2	p.G391R	1:16464489..16464489	PMID: 20360610	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	BMX#p.G424E	BMX	p.G424E	X:15555305..15555305	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	BRAF#p.G466V	BRAF	p.G466V	7:140481411..140481411	PMID: 22649091	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.G505S	DDR2	p.G505S	1:162741822..162741822	PMID: 22328973	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.G774V	DDR2	p.G774V	1:162748407..162748407	PMID: 22328973	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.I638F	DDR2	p.I638F	1:162745497..162745497	PMID: 22328973	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.K106N	ABL1	p.K106N	9:133730195..133730195	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	BTK#p.K60E	BTK	p.K60E	X:100629586..100629586	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.L239R	DDR2	p.L239R	1:162729630..162729630	PMID: 22328973	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.L273M	ABL1	p.L273M	9:133738417..133738417	PMID: 20673586	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	BTK#p.L528F	BTK	p.L528F	X:100609665..100609665	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT#p.L576P	KIT	p.L576P	4:55593661..55593661	PMID: 17372901, 18448188	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.L63V	DDR2	p.L63V	1:162724415..162724415	PMID: 22328973	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 23149070	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.R783G	ABL1	p.R783G	9:133759967..133759967	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.S768R	DDR2	p.S768R	1:162748390..162748390	PMID: 22328973	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315A	ABL1	p.T315A	9:133748282..133748282	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315A	ABL1	p.T315A	9:133748282..133748282	PMID: 23044928	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21931113	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 26308885	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21357704	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 22873741	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21264552	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.T495R	ABL1	p.T495R	9:133755515..133755515	PMID: 19260121	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	CSF3R#p.T615A	CSF3R	p.T615A	1:36933444..36933444	PMID: 23656643	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	CSF3R#p.T618I	CSF3R	p.T618I	1:36933434..36933434	PMID: 23656643	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
dasatinib	dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	DDR2#p.T654I	DDR2	p.T654I	1:162745546..162745546	PMID: 24296828	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	.	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	SRC#p.V140M	SRC	p.V140M	20:36022365..36022365	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）		白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 26308885	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 23086624	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.V379I	ABL1	p.V379I	9:133750304..133750304	PMID: 20673586	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.V390L	ABL1	p.V390L	9:133750280..133750280	.	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 20673586	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21562040	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21357704	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21264552	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1#p.Y353H	ABL1	p.Y353H	9:133748396..133748396	PMID: 20673586	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	CBL#p.Y371H	CBL	p.Y371H	11:119148891..119148891	PMID: 23696637	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	BRAF#p.Y472C	BRAF	p.Y472C	7:140481393..140481393	PMID: 22649091	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24296828	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1__BCR	ABL1	ABL1-BCR fusion	ABL1范围：9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12;BCR范围：22:23523097..23524436..exon1,23595975..23596177..exon2,23603126..23603251..exon3,23603531..23603737..exon4,23610584..23610712..exon5,23613708..23613789..exon6,23615257..23615330..exon7,23615810..23615971..exon8,23626153..23626295..exon9,23627209..23627398..exon10,23629335..23629475..exon11,23630273..23630369..exon12,23631693..23631818..exon13,23632515..23632610..exon14,23634717..23634835..exon15,23637200..23637352..exon16,23651600..23651680..exon17,23652500..23652630..exon18,23653873..23654033..exon19,23655063..23655218..exon20,23656144..23656270..exon21,23656728..23656911..exon22,23657609..23657759..exon23	PMID: 27582059	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	ABL1__BCR	ABL1	ABL1-BCR fusion	ABL1范围：9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12;BCR范围：22:23523097..23524436..exon1,23595975..23596177..exon2,23603126..23603251..exon3,23603531..23603737..exon4,23610584..23610712..exon5,23613708..23613789..exon6,23615257..23615330..exon7,23615810..23615971..exon8,23626153..23626295..exon9,23627209..23627398..exon10,23629335..23629475..exon11,23630273..23630369..exon12,23631693..23631818..exon13,23632515..23632610..exon14,23634717..23634835..exon15,23637200..23637352..exon16,23651600..23651680..exon17,23652500..23652630..exon18,23653873..23654033..exon19,23655063..23655218..exon20,23656144..23656270..exon21,23656728..23656911..exon22,23657609..23657759..exon23	FDA	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	CSF3R#p.S783fs	CSF3R	CSF3R frameshift variant (D771),frameshift variant (S783)	1:36931646..36931811..exon1,36931907..36932438..exon2,36931907..36932519..exon3,36932211..36932438..exon4,36932820..36932922..exon5,36933148..36933262..exon6,36933412..36933573..exon7,36933665..36933832..exon8,36934746..36934868..exon9,36935242..36935451..exon10,36937023..36937257..exon11,36937656..36937750..exon12,36937828..36938002..exon13,36938107..36938297..exon14,36939025..36939233..exon15,36939354..36939498..exon16,36940967..36941284..exon17,36945023..36945147..exon18	PMID: 23656643	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	CSF3R#p.D771fs	CSF3R	CSF3R frameshift variant (D771),frameshift variant (S783)	1:36931646..36931811..exon1,36931907..36932438..exon2,36931907..36932519..exon3,36932211..36932438..exon4,36932820..36932922..exon5,36933148..36933262..exon6,36933412..36933573..exon7,36933665..36933832..exon8,36934746..36934868..exon9,36935242..36935451..exon10,36937023..36937257..exon11,36937656..36937750..exon12,36937828..36938002..exon13,36938107..36938297..exon14,36939025..36939233..exon15,36939354..36939498..exon16,36940967..36941284..exon17,36945023..36945147..exon18	PMID: 23656643	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	EPHA2:amp	EPHA2	EPHA2 amplification	1:16451659..16451825..exon1,16455918..16456094..exon2,16456710..16456924..exon3,16458205..16458375..exon4,16458548..16458778..exon5,16458862..16458944..exon6,16459664..16459873..exon7,16459965..16460111..exon8,16460344..16460420..exon9,16460952..16461072..exon10,16461520..16461694..exon11,16462139..16462275..exon12,16464337..16464690..exon13,16464759..16464935..exon14,16474862..16475552..exon15,16474862..16475583..exon16,16477380..16477468..exon17,16482332..16482477..exon18	PMID: 18047674, 19010823, 19861960	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	IDH1:.	IDH1	IDH1 oncogenic mutation	2:209101752..209101903..exon1,209103784..209103967..exon2,209104576..209104737..exon3,209106707..209106879..exon4,209108140..209108338..exon5,209110032..209110158..exon6,209113082..209113394..exon7,209116143..209116325..exon8	NCT02428855	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	IDH1:R132.	IDH1	IDH1 R132*	2:209101752..209101903..exon1,209103784..209103967..exon2,209104576..209104737..exon3,209106707..209106879..exon4,209108140..209108338..exon5,209110032..209110158..exon6,209113082..209113394..exon7,209116143..209116325..exon8	PMID: 27231123	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	IDH2:.	IDH2	IDH2 oncogenic mutation	15:90627447..90627595..exon1,90628037..90628150..exon2,90628222..90628340..exon3,90628496..90628629..exon4,90630333..90630505..exon5,90630660..90630817..exon6,90631580..90631744..exon7,90631808..90631989..exon8,90631808..90632012..exon9,90633700..90633886..exon10,90634774..90634885..exon11,90634774..90634886..exon12,90645497..90645672..exon13	NCT02428855	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT:550-592,627-664	KIT	KIT mutation in exon 9,11,13,14 or 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 19671763	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	KIT::wildtype:.	KIT	KIT wildtype	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 16397263	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
dasatinib	dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	NF1 loss	NF1	NF1 loss	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24296828	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	.	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24296828	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病	II
Dasatinib	Dasatinib (达沙替尼)	ABL1;KIT;PDGFRA	PDGFRA::wildtype:.	PDGFRA	PDGFRA wildtype	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	PMID: 16397263	NCT00608361:Phase 1:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.A289V	EGFR	p.A289V	7:55221822..55221822	PMID: 17177598	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.D761Y	EGFR	p.D761Y	7:55242511..55242511	PMID: 19680293	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.E746G	EGFR	p.E746G	7:55242467..55242467	PMID: 26773740	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.G598V	EGFR	p.G598V	7:55233043..55233043	PMID: 17177598	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.G719A	EGFR	p.G719A	7:55241708..55241708	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.G719D	EGFR	p.G719D	7:55241708..55241708	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.G721V	EGFR	p.G721V	7:55241714..55241714	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.I789M	EGFR	p.I789M	7:55249069..55249069	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.K716R	EGFR	p.K716R	7:55241699..55241699	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.K757R	EGFR	p.K757R	7:55242500..55242500	PMID: 26773740	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.N842H	EGFR	p.N842H	7:55259466..55259466	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.R108K	EGFR	p.R108K	7:55211080..55211080	PMID: 17177598	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.S720C	EGFR	p.S720C	7:55241711..55241711	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.S768I	EGFR	p.S768I	7:55249005..55249005	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	DDR2#p.S768R	DDR2	p.S768R	1:162748390..162748390	PMID: 22328973	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.T263P	EGFR	p.T263P	7:55221743..55221743	PMID: 17177598	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 21430269	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 24781527	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.V742I	EGFR	p.V742I	7:55242454..55242454	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.V769L	EGFR	p.V769L	7:55249007..55249007	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.V774M	EGFR	p.V774M	7:55249022..55249022	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR::consequence::inframe_deletion:729-761	EGFR	EGFR exon 19 deletions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR::consequence::inframe_insertion:729-761	EGFR	EGFR exon 19 insertions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 22190593	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR::consequence::inframe_insertion:769-770	EGFR	EGFR inframe insertion (769-770)	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 26773740, 23328547	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24535670	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24634382	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 22434731	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF2:del	NF2	NF2 deletion	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 20736812	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF2:del;EGFR:.	EGFR	NF2 deletion + EGFR oncogenic mutation	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 24813888	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF2:del;EGFR:.	NF2	NF2 deletion + EGFR oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 24813888	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.771in_frame_insSVD	EGFR	p.771in_frame_insSVD	7:55249148..55249150	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR#p.ELREA746in_frame_del	EGFR	p.ELREA746in_frame_ del	7:55249073..55249075	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR:L858R,L861.,G719.,S768I	EGFR	EGFR (L858R,L861,G719,S768I)	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	.	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR:S720.	EGFR	EGFR (S720)	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 26773740	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR:amp	EGFR	EGFR amplification	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	ASCO2015(abstre19028)	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR__RAD51	EGFR	EGFR-RAD51 fusion	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 27102076	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	EGFR__RAD51	EGFR	EGFR-RAD51 fusion	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 27102076	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	IGF1R:amp	IGF1R	IGF1R amplification	15:99192760..99192914..exon1,99250780..99251346..exon2,99434543..99434876..exon3,99439975..99440144..exon4,99442695..99442860..exon5,99451903..99452138..exon6,99454533..99454680..exon7,99456262..99456521..exon8,99459182..99459370..exon9,99459890..99460115..exon10,99465366..99465670..exon11,99467094..99467251..exon12,99467743..99467923..exon13,99472776..99472899..exon14,99472779..99472899..exon15,99473453..99473544..exon16,99478042..99478292..exon17,99478534..99478665..exon18,99482419..99482599..exon19,99486141..99486291..exon20,99491792..99491947..exon21,99500279..99500721..exon22	PMID: 24458568	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24535670	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24634382	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 22434731	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF2:.	NF2	NF2 oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 20736812	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF2:.;EGFR:.	EGFR	NF2 oncogenic mutation + EGFR oncogenic mutation	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 24813888	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加;不推荐与铂类化疗药物使用	肺癌; 胰腺癌	II
Erlotinib	Erlotinib (厄洛替尼)	EGFR;NR1I2	NF2:.;EGFR:.	NF2	NF2 oncogenic mutation + EGFR oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 24813888	NCT00605722:Phase 2:Completed:No publish||NCT00881751:Phase 2:Completed:No publish||NCT00365391:Phase 2:Completed:No publish||NCT00242502:Phase 2:Completed:No publish||NCT01180959:Phase 2:Active, not recruiting:No publish||NCT00047346:Phase 1:Completed:No publish||NCT02273362:Phase 1|Phase 2:Recruiting:No publish||NCT00987766:Phase 1:Completed:No publish||NCT00033462:Phase 2:Completed:No publish||NCT00397384:Phase 1:Completed:No publish||NCT00030498:Phase 1:Completed:No publish||NCT00901901:Phase 3:Completed:No publish||NCT00287222:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加;不推荐与铂类化疗药物使用	肺癌; 胰腺癌	II
Everolimus	Everolimus (依维莫司)	MTOR	HER2 amplification	HER2	HER2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 20453058, 23714559	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PI3KCA oncogenic mutation	PIK3CA	PI3KCA oncogenic mutation	3:178916563..178916975..exon1,178917467..178917697..exon2,178919067..178919338..exon3,178921321..178921587..exon4,178922280..178922386..exon5,178927372..178927498..exon6,178927963..178928136..exon7,178928208..178928363..exon8,178935987..178936132..exon9,178936973..178937075..exon10,178937348..178937533..exon11,178937726..178937850..exon12,178938763..178938955..exon13,178941858..178941985..exon14,178942477..178942619..exon15,178943739..178943838..exon16,178947049..178947240..exon17,178947781..178947919..exon18,178948002..178948174..exon19,178951871..178952202..exon20	PMID: 22932669, 23714559	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PI3KCA oncogenic mutation	PIK3CA	PI3KCA oncogenic mutation	3:178916563..178916975..exon1,178917467..178917697..exon2,178919067..178919338..exon3,178921321..178921587..exon4,178922280..178922386..exon5,178927372..178927498..exon6,178927963..178928136..exon7,178928208..178928363..exon8,178935987..178936132..exon9,178936973..178937075..exon10,178937348..178937533..exon11,178937726..178937850..exon12,178938763..178938955..exon13,178941858..178941985..exon14,178942477..178942619..exon15,178943739..178943838..exon16,178947049..178947240..exon17,178947781..178947919..exon18,178948002..178948174..exon19,178951871..178952202..exon20	PMID: 20453058, 23714559	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PTEN loss (Loss of PTEN activity)	PTEN	PTEN loss (Loss of PTEN activity)	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	PMID: 22932669, 23714559	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	TSC1#p.E636fs	TSC1	p.E636fs	9:135781057..135781058	PMID: 22923433	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	FGFR4#p.G388R	FGFR4	p.G388R	5:176520243..176520243	PMID:  22986737	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	FLCN:del	FLCN	FLCN deletion	17:17116918..17117180..exon1,17118288..17118414..exon2,17118488..17118640..exon3,17119683..17119827..exon4,17120372..17120506..exon5,17122322..17122533..exon6,17124642..17124952..exon7,17124840..17124952..exon8,17125804..17125985..exon9,17127225..17127467..exon10,17129479..17129646..exon11,17131192..17131501..exon12	PMID: 25295501	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT01365468	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 26859683;ASCO 2016 (abstr e17557)	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	ASCO 2016 (abstr 11053)	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24634382	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF2:del	NF2	NF2 deletion	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 24311643;2556735	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF2:del	NF2	NF2 deletion	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 26015296	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PBRM1:under	PBRM1	PBRM1 undexpression	3:52582028..52582261..exon1,52584426..52584663..exon2,52584752..52584843..exon3,52588729..52588905..exon4,52595772..52595994..exon5,52597288..52597519..exon6,52597369..52597519..exon7,52598055..52598259..exon8,52610546..52610724..exon9,52613059..52613225..exon10,52620430..52620714..exon11,52621358..52621461..exon12,52621358..52621536..exon13,52623075..52623278..exon14,52623075..52623281..exon15,52637526..52637758..exon16,52643318..52643981..exon17,52649356..52649482..exon18,52651267..52651564..exon19,52658902..52658967..exon20,52661278..52661396..exon21,52662899..52663061..exon22,52668607..52668841..exon23,52675959..52676071..exon24,52677253..52677369..exon25,52678709..52678815..exon26,52682349..52682468..exon27,52685747..52685836..exon28,52692204..52692341..exon29,52696138..52696302..exon30,52702503..52702671..exon31,52712505..52712623..exon32,52713579..52713752..exon33,52713579..52713777..exon34,52715700..52715808..exon35,52715709..52715808..exon36	PMID: 25997916	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PTEN:del	PTEN	PTEN deletion	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	PMID: 23582881	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 21107682, 20975068	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	ERBB2:norm;ESR1:over	ERBB2	ERBB2 expression + ESR1 overexpression	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	ERBB2:norm;ESR1:over	ESR1	ERBB2 expression + ESR1 overexpression	6:152128997..152129509..exon1,152163721..152163932..exon2,152163721..152163938..exon3,152163748..152163932..exon4,152201779..152201913..exon5,152201779..152201916..exon6,152265297..152265653..exon7,152332780..152332939..exon8,152382115..152382269..exon9,152415509..152415713..exon10,152419856..152420151..exon11,152446390..152446533..exon12	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	FLCN:.	FLCN	FLCN oncogenic mutation	17:17116918..17117180..exon1,17118288..17118414..exon2,17118488..17118640..exon3,17119683..17119827..exon4,17120372..17120506..exon5,17122322..17122533..exon6,17124642..17124952..exon7,17124840..17124952..exon8,17125804..17125985..exon9,17127225..17127467..exon10,17129479..17129646..exon11,17131192..17131501..exon12	PMID: 23995526	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT01365468	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	NCT01365468	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 26859683;ASCO 2016 (abstr e17557)	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	ASCO 2016 (abstr 11053)	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24634382	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24931142	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF2:.	NF2	NF2 oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 24311643;2556735	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	NF2:.	NF2	NF2 oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 26015296	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PIK3CA:.;ERBB2:amp	ERBB2	PIK3CA oncogenic mutation + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 27091708	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PIK3CA:.;ERBB2:amp	PIK3CA	PIK3CA oncogenic mutation + ERBB2 amplification	3:178916563..178916975..exon1,178917467..178917697..exon2,178919067..178919338..exon3,178921321..178921587..exon4,178922280..178922386..exon5,178927372..178927498..exon6,178927963..178928136..exon7,178928208..178928363..exon8,178935987..178936132..exon9,178936973..178937075..exon10,178937348..178937533..exon11,178937726..178937850..exon12,178938763..178938955..exon13,178941858..178941985..exon14,178942477..178942619..exon15,178943739..178943838..exon16,178947049..178947240..exon17,178947781..178947919..exon18,178948002..178948174..exon19,178951871..178952202..exon20	PMID: 27091708	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PIK3CG oncogenic mutation	PIK3CG	PIK3CG oncogenic mutation	7:106507956..106510011..exon1,106512971..106513057..exon2,106513147..106513393..exon3,106515134..106515258..exon4,106519953..106520120..exon5,106522551..106522662..exon6,106523467..106523618..exon7,106524589..106524721..exon8,106526569..106526747..exon9,106545543..106545882..exon10	PMID: 29285035	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PTEN:.	PTEN	PTEN oncogenic mutation	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	PMID: 23582881	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PTEN:.;ERBB2:amp	ERBB2	PTEN oncogenic mutation + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 27091708	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Everolimus	Everolimus (依维莫司)	MTOR	PTEN:.;ERBB2:amp	PTEN	PTEN oncogenic mutation + ERBB2 amplification	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	PMID: 27091708	NCT01005199:Phase 2:Completed:No publish||NCT01642186:Phase 2:Active, not recruiting:No publish||NCT02081755:Phase 4:Recruiting:No publish||NCT01423708:Phase 2:Unknown status:No publish||NCT01469572:Phase 1:Active, not recruiting:No publish||NCT01488487:Phase 2:Completed:No publish||NCT01035229:Phase 3:Completed:No publish||NCT01035229:Phase 3:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌; 肾癌; 胰腺癌;胃肠道神经内分泌瘤	II
Foretinib	Foretinib	MET;RON;ERK; AKT	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 26924578;NCT00920192:Phase 1:Completed:No publish	.	否	否	敏感性增加	乳腺癌;癌;肾细胞;复发性乳腺癌;肿瘤;头部和颈部;等等	III
Foretinib	Foretinib	MET;RON;ERK; AKT	PTCH1:.	PTCH1	PTCH1 oncogenic mutation	9:98209143..98209743..exon1,98211340..98211615..exon2,98212112..98212232..exon3,98215749..98215912..exon4,98218547..98218705..exon5,98220284..98220585..exon6,98221871..98222075..exon7,98224127..98224290..exon8,98229387..98229717..exon9,98231022..98231445..exon10,98232084..98232223..exon11,98238305..98238451..exon12,98239030..98239149..exon13,98239818..98239994..exon14,98240326..98240478..exon15,98241271..98241439..exon16,98242240..98242382..exon17,98242661..98242880..exon18,98244220..98244332..exon19,98244405..98244495..exon20,98247956..98248147..exon21,98247956..98248166..exon22,98268678..98268891..exon23,98270432..98270693..exon24,98278740..98278803..exon25,98278894..98279152..exon26	PMID: 25391241;NCT00920192:Phase 1:Completed:No publish	.	否	否	敏感性增加	乳腺癌;癌;肾细胞;复发性乳腺癌;肿瘤;头部和颈部;等等	III
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.G719A	EGFR	p.G719A	7:55241708..55241708	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.G719A	EGFR	p.G719A	7:55241708..55241708	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.G719C	EGFR	p.G719C	7:55241707..55241707	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.G719D	EGFR	p.G719D	7:55241708..55241708	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.G719D	EGFR	p.G719D	7:55241708..55241708	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.G719S	EGFR	p.G719S	7:55241707..55241707	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.G721V	EGFR	p.G721V	7:55241714..55241714	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.I789M	EGFR	p.I789M	7:55249069..55249069	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.K716R	EGFR	p.K716R	7:55241699..55241699	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.L747S	EGFR	p.L747S	7:55242470..55242470	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	NCT00071994:Phase 2:Completed:No publish	FDA guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.L861P	EGFR	p.L861P	7:55259524..55259524	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.L861Q	EGFR	p.L861Q	7:55259524..55259524	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.L861R	EGFR	p.L861R	7:55259524..55259524	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.N842H	EGFR	p.N842H	7:55259466..55259466	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.S720C	EGFR	p.S720C	7:55241711..55241711	NCT00071994:Phase 2:Completed:No publish	prediction	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.S768I	EGFR	p.S768I	7:55249005..55249005	NCT00071994:Phase 2:Completed:No publish	NCCN guidelines	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 18509184	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 20686428	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 20871262	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 21030498	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 22215752	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 22815900	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 23180674	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 23407566	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	PMID: 23886554	NCT00071994:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	.	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	NCT00071994:Phase 2:Completed:No publish	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.V742I	EGFR	p.V742I	7:55242454..55242454	NCT00071994:Phase 2:Completed:No publish	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.V769L	EGFR	p.V769L	7:55249007..55249007	NCT00071994:Phase 2:Completed:No publish	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.V774M	EGFR	p.V774M	7:55249022..55249022	NCT00071994:Phase 2:Completed:No publish	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.V843I	EGFR	p.V843I	7:55259469..55259469	PMID: 21274259	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	敏感性降低	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR::consequence::inframe_deletion:729-761	EGFR	EGFR exon 19 deletions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	NCT00071994:Phase 2:Completed:No publish	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR::consequence::inframe_deletion:L747.,::inframe_insertion:P753PS	EGFR	EGFR inframe deletion (L747),inframe insertion (P753PS)	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 21274259	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	敏感性降低	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.771in_frame_insSVD	EGFR	p.771in_frame_insSVD	7:55249148..55249150	NCT00071994:Phase 2:Completed:No publish	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR#p.ELREA746in_frame_del	EGFR	p.ELREA746in_frame_ del	7:55249073..55249075	NCT00071994:Phase 2:Completed:No publish	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	耐药性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR:amp	EGFR	EGFR amplification	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 21274259, 22261807	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	敏感性降低	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Gefitinib	Gefitinib (吉非替尼)	EGFR	EGFR:amp	EGFR	EGFR amplification	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 24950987	NCT00352079: 膀胱癌; NCT01243398: 胃癌，食管癌	是（非本癌种）	是（非本癌种）	敏感性增加	该药物适用于EGFR 19外显子缺失或21外显子L858R突变的非小细胞肺癌患者，除此外的EGFR突变患者使用该药物的安全性和有效性暂不清楚。	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.?	ABL1	.	9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.?fs	KIT	?fs	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A344V	ABL1	p.A344V	9:133748370..133748370	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A350V	ABL1	p.A350V	9:133748388..133748388	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A365V	ABL1	p.A365V	9:133750263..133750263	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A366G	ABL1	p.A366G	9:133750266..133750266	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A380T	ABL1	p.A380T	9:133750307..133750307	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A397P	ABL1	p.A397P	9:133750358..133750358	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A397P	ABL1	p.A397P	9:133750358..133750358	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A397P	ABL1	p.A397P	9:133750358..133750358	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A397P	ABL1	p.A397P	9:133750358..133750358	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A399T	ABL1	p.A399T	9:133750307..133750307	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A433T	ABL1	p.A433T	9:133753828..133753828	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A433T	ABL1	p.A433T	9:133753828..133753828	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.A433T	ABL1	p.A433T	9:133753828..133753828	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.A829P	KIT	p.A829P	4:55602664..55602664	PMID: 23582185, 21689725, 17259998	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.A829P	KIT	p.A829P	4:55602664..55602664	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.A829P	KIT	p.A829P	4:55602664..55602664	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.A829P	KIT	p.A829P	4:55602664..55602664	PMID: 23456621	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.A829P	KIT	p.A829P	4:55602664..55602664	PMID: 26779618	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.C809G	KIT	p.C809G	4:55599299..55599299	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.C809G	KIT	p.C809G	4:55599299..55599299	PMID: 17875769	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.C809G	KIT	p.C809G	4:55599299..55599299	PMID: 18452195	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.C809G	KIT	p.C809G	4:55599299..55599299	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276A	ABL1	p.D276A	9:133747520..133747520	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276G	ABL1	p.D276G	9:133747520..133747520	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276G	ABL1	p.D276G	9:133747520..133747520	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276G	ABL1	p.D276G	9:133747520..133747520	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276G	ABL1	p.D276G	9:133747520..133747520	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276G	ABL1	p.D276G	9:133747520..133747520	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276G	ABL1	p.D276G	9:133747520..133747520	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D276N	ABL1	p.D276N	9:133747518..133747519	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D363Y	ABL1	p.D363Y	9:133750256..133750256	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D400Y	ABL1	p.D400Y	9:133750310..133750310	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.D482V	ABL1	p.D482V	9:133755476..133755476	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D716N	KIT	p.D716N	4:55597498..55597498	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816A	KIT	p.D816A	4:55599321..55599321	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816E	KIT	p.D816E	4:55599334..55599334	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816E	KIT	p.D816E	4:55599334..55599334	PMID: 18452195	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816G	KIT	p.D816G	4:55599321..55599321	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816H	KIT	p.D816H	4:55599320..55599320	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816H	KIT	p.D816H	4:55599320..55599320	PMID: 17875769	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816H	KIT	p.D816H	4:55599320..55599320	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816H	KIT	p.D816H	4:55599320..55599320	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D816H	KIT	p.D816H	4:55599320..55599320	PMID: 20032375	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820A	KIT	p.D820A	4:55599333..55599333	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820A	KIT	p.D820A	4:55599333..55599333	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820E	KIT	p.D820E	4:55599334..55599334	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820E	KIT	p.D820E	4:55599334..55599334	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820E	KIT	p.D820E	4:55599334..55599334	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820E	KIT	p.D820E	4:55599334..55599334	PMID: 18452195	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820E	KIT	p.D820E	4:55599334..55599334	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820G	KIT	p.D820G	4:55599333..55599333	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820G	KIT	p.D820G	4:55599333..55599333	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820G	KIT	p.D820G	4:55599333..55599333	PMID: 18452195	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820G	KIT	p.D820G	4:55599333..55599333	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820G	KIT	p.D820G	4:55599333..55599333	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820G	KIT	p.D820G	4:55599333..55599333	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 23775962	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 15930355	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 18452195	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 23456621	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D820Y	KIT	p.D820Y	4:55599332..55599332	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 22718859, 16638875	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 12949711	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 14645423	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 15930355	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 20043176	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 20568982	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 22718859	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 26130666	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D861H	KIT	p.D861H	4:55602772..55602774/c.2581..2583/p.861L	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 11853795	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 23355941	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 25807654	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 11853795	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255K	ABL1	p.E255K	9:133738306..133738306	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 11853795	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E255V	ABL1	p.E255V	9:133738307..133738307	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E258D	ABL1	p.E258D	9:133738374..133738374	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E275K	ABL1	p.E275K	9:133747516..133747516	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E275K	ABL1	p.E275K	9:133747516..133747516	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E275Q	ABL1	p.E275Q	9:133747516..133747516	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E279A	ABL1	p.E279A	9:133747529..133747529	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E279K	ABL1	p.E279K	9:133747528..133747528	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E279K	ABL1	p.E279K	9:133747528..133747528	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E279Y	ABL1	p.E279Y	9:133747528..133747530delnsTAT	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E279Z	ABL1	p.E279Z	9:133747528..133747530/c.835..837/p.E279	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E282G	ABL1	p.E282G	9:133747538..133747538	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E292Q	ABL1	p.E292Q	9:133747567..133747567	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E292V	ABL1	p.E292V	9:133747568..133747568	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E292V	ABL1	p.E292V	9:133747568..133747568	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E292V	ABL1	p.E292V	9:133747568..133747568	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E352D	ABL1	p.E352D	9:133748395..133748395	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E352G	ABL1	p.E352G	9:133748394..133748394	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355?	ABL1	p.E355?	9:133748402..133748404/c.1063..1065/p.E355	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355A	ABL1	p.E355A	9:133748403..133748403	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355A	ABL1	p.E355A	9:133748403..133748403	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355A	ABL1	p.E355A	9:133748403..133748403	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355D	ABL1	p.E355D	9:133748404..133748404	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 25740611	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E355G	ABL1	p.E355G	9:133748403..133748403	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E373K	ABL1	p.E373K	9:133750286..133750286	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450?	ABL1	p.E450?	9:133753822..133753824/c.1348..1350/p.E450	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450A	ABL1	p.E450A	9:133753823..133753823	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450A	ABL1	p.E450A	9:133753823..133753823	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450A	ABL1	p.E450A	9:133753823..133753823	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450G	ABL1	p.E450G	9:133753823..133753823	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450G	ABL1	p.E450G	9:133753823..133753823	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450G	ABL1	p.E450G	9:133753823..133753823	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450G	ABL1	p.E450G	9:133753823..133753823	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450K	ABL1	p.E450K	9:133753822..133753822	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450K	ABL1	p.E450K	9:133753822..133753822	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E450V	ABL1	p.E450V	9:133753823..133753823	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453A	ABL1	p.E453A	9:133753889..133753889	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453A	ABL1	p.E453A	9:133753889..133753889	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453D	ABL1	p.E453D	9:133753890..133753890	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453G	ABL1	p.E453G	9:133753889..133753889	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453G	ABL1	p.E453G	9:133753889..133753889	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453K	ABL1	p.E453K	9:133753888..133753888	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453K	ABL1	p.E453K	9:133753888..133753888	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453K	ABL1	p.E453K	9:133753888..133753888	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453L	ABL1	p.E453L	9:133753888..133753889delinsCT	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E453V	ABL1	p.E453V	9:133753889..133753889	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459A	ABL1	p.E459A	9:133753907..133753907	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459G	ABL1	p.E459G	9:133753907..133753907	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459G	ABL1	p.E459G	9:133753907..133753907	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459G	ABL1	p.E459G	9:133753907..133753907	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459G	ABL1	p.E459G	9:133753907..133753907	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459K	ABL1	p.E459K	9:133753906..133753906	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459Q	ABL1	p.E459Q	9:133753906..133753906	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E459V	ABL1	p.E459V	9:133753907..133753907	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.E490K	KIT	p.E490K	4:55592144..55592144	PMID: 21325067	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E494G	ABL1	p.E494G	9:133755512..133755512	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.E507G	ABL1	p.E507G	9:133755893..133755893	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	DDR1#p.E618Q	DDR1	p.E618Q	6:30864625..30864625	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311I	ABL1	p.F311I	9:133748270..133748270	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311I	ABL1	p.F311I	9:133748270..133748270	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311I	ABL1	p.F311I	9:133748270..133748270	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311I	ABL1	p.F311I	9:133748270..133748270	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311I	ABL1	p.F311I	9:133748270..133748270	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311I	ABL1	p.F311I	9:133748270..133748270	PMID: 21264552	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311L	ABL1	p.F311L	9:133748270..133748270	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311L	ABL1	p.F311L	9:133748270..133748270	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F311L	ABL1	p.F311L	9:133748270..133748270	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317C	ABL1	p.F317C	9:133748289..133748289	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317I	ABL1	p.F317I	9:133748288..133748288	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 21264552	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317L	ABL1	p.F317L	9:133748288..133748288	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317V	ABL1	p.F317V	9:133748288..133748288	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F317V	ABL1	p.F317V	9:133748288..133748288	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359*	ABL1	p.F359*	9:133748415..133748416delTCinsAA	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359?	ABL1	p.F359?	9:133748414..133748416/c.1075..1077/p.F359	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359?	ABL1	p.F359?	9:133748414..133748416/c.1075..1077/p.F359	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359A	ABL1	p.F359A	9:133748414..133748415delTTins	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359C	ABL1	p.F359C	9:133748415..133748415	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 23044928	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359I	ABL1	p.F359I	9:133748414..133748414	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359L	ABL1	p.F359L	9:133748414..133748414	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F359V	ABL1	p.F359V	9:133748414..133748414	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F382L	ABL1	p.F382L	9:133750313..133750313	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F382L	ABL1	p.F382L	9:133750313..133750313	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F382L	ABL1	p.F382L	9:133750313..133750313	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F401L	ABL1	p.F401L	9:133750370..133750370	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.F486S	ABL1	p.F486S	9:133755488..133755488	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 20682399	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 25807654	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 26413254	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 21264552	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250E	ABL1	p.G250E	9:133738349..133738349	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G250R	ABL1	p.G250R	9:133738348..133738348	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G251D	ABL1	p.G251D	9:133738352..133738352	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G251E	ABL1	p.G251E	9:133738352..133738353delinsAG	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.G398R	ABL1	p.G398R	9:133750361..133750361	PMID: 25740611	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	DDR1#p.G731R	DDR1	p.G731R	6:30865331..30865331	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.G812V	KIT	p.G812V	4:55599309..55599309	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.G853D	PDGFRA	p.G853D	4:55152126..55152126	PMID: 24132921	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396A	ABL1	p.H396A	9:133750355..133750356delCAins	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396P	ABL1	p.H396P	9:133750356..133750356	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396P	ABL1	p.H396P	9:133750356..133750356	PMID: 11853795	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396P	ABL1	p.H396P	9:133750356..133750356	PMID: 22299775	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396P	ABL1	p.H396P	9:133750356..133750356	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396P	ABL1	p.H396P	9:133750356..133750356	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.H396R	ABL1	p.H396R	9:133750356..133750356	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.H697Y	KIT	p.H697Y	4:55595599..55595599	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.H845Y	PDGFRA	p.H845Y	4:55152101..55152101	PMID: 24132921	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.I242T	ABL1	p.I242T	9:133738325..133738325	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.I293V	ABL1	p.I293V	9:133747570..133747570	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.I418S	ABL1	p.I418S	9:133750422..133750422	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.I418V	ABL1	p.I418V	9:133750421..133750421	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.I418V	ABL1	p.I418V	9:133750421..133750421	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.I418V	ABL1	p.I418V	9:133750421..133750421	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.I571K	KIT	p.I571K	4:55593646..55593646	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.K106N	ABL1	p.K106N	9:133730195..133730195	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.K247R	ABL1	p.K247R	9:133738340..133738340	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.K294>RGG	ABL1	p.K294>RGG	9:133747573..133747574	PMID: 21264552	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.K294RGG	ABL1	p.K294RGG	9:133747573..133747575/c.880..882/p.K294	PMID: 21264552	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.K378R	ABL1	p.K378R	9:133750302..133750302	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.K419E	ABL1	p.K419E	9:133750424..133750424	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.K642E	KIT	p.K642E	4:55594221..55594221	PMID: 20043176	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.K642E	KIT	p.K642E	4:55594221..55594221	PMID: 20043176	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.K642E	KIT	p.K642E	4:55594221..55594221	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.K642E	KIT	p.K642E	4:55594221..55594221	PMID: 18066592	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.K818_D820>N	KIT	p.K818_D820>N	4:55599326..55599334	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 17008892	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L248V	ABL1	p.L248V	9:133738342..133738342	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L273M	ABL1	p.L273M	9:133738417..133738417	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L273M	ABL1	p.L273M	9:133738417..133738417	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L273M	ABL1	p.L273M	9:133738417..133738417	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L298V	ABL1	p.L298V	9:133747585..133747585	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L298V	ABL1	p.L298V	9:133747585..133747585	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L298V	ABL1	p.L298V	9:133747585..133747585	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L298V	ABL1	p.L298V	9:133747585..133747585	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L298V	ABL1	p.L298V	9:133747585..133747585	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L324Q	ABL1	p.L324Q	9:133748310..133748310	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L324Q	ABL1	p.L324Q	9:133748310..133748310	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L340L	ABL1	p.L340L	9:133748359..133748359	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L364I	ABL1	p.L364I	9:133750259..133750259	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L364I	ABL1	p.L364I	9:133750259..133750259	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L364I	ABL1	p.L364I	9:133750259..133750259	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L364I	ABL1	p.L364I	9:133750259..133750259	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L364I	ABL1	p.L364I	9:133750259..133750259	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L370P	ABL1	p.L370P	9:133750278..133750278	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L384M	ABL1	p.L384M	9:133750319..133750319	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L384M	ABL1	p.L384M	9:133750319..133750319	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L384M	ABL1	p.L384M	9:133750319..133750319	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L384M	ABL1	p.L384M	9:133750319..133750319	PMID: 26413254	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387F	ABL1	p.L387F	9:133750330..133750330	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387F	ABL1	p.L387F	9:133750330..133750330	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387M	ABL1	p.L387M	9:133750328..133750328	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.L387V	ABL1	p.L387V	9:133750328..133750328	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.L576P	KIT	p.L576P	4:55593661..55593661	PMID: 18066592	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.L576P	KIT	p.L576P	4:55593661..55593661	PMID: 17372901, 18448188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M237V	ABL1	p.M237V	9:133738309..133738309	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 22299775	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 19156415	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M244V	ABL1	p.M244V	9:133738330..133738330	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M343T	ABL1	p.M343T	9:133748367..133748367	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M343T	ABL1	p.M343T	9:133748367..133748367	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351K	ABL1	p.M351K	9:133748391..133748391	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 15381060	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 23355941	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M351T	ABL1	p.M351T	9:133748391..133748391	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M388L	ABL1	p.M388L	9:133750331..133750331	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M388L	ABL1	p.M388L	9:133750331..133750331	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M388L	ABL1	p.M388L	9:133750331..133750331	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.M472I	ABL1	p.M472I	9:133753947..133753947	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.N368S	ABL1	p.N368S	9:133750272..133750272	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.N374Y	ABL1	p.N374Y	9:133750289..133750289	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N680K	KIT	p.N680K	4:55595550..55595550	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 15930355	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 17875769	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 23456621	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 26316776	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822Y	KIT	p.N822Y	4:55599338..55599338	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822Y	KIT	p.N822Y	4:55599338..55599338	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.N822Y	KIT	p.N822Y	4:55599338..55599338	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.P310S	ABL1	p.P310S	9:133748267..133748267	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.P480L	ABL1	p.P480L	9:133753913..133753913	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.P480L	ABL1	p.P480L	9:133753913..133753913	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.P577S	PDGFRA	p.P577S	4:55141083..55141083	PMID: 24132921	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252E	ABL1	p.Q252E	9:133738354..133738354	PMID: 15381060	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 22489663	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252H	ABL1	p.Q252H	9:133738356..133738356	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252K	ABL1	p.Q252K	9:133738354..133738354	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252M	ABL1	p.Q252M	9:133738354..133738355delCAinsAT	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252R	ABL1	p.Q252R	9:133738355..133738355	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Q252R	ABL1	p.Q252R	9:133738355..133738355	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.R328M	ABL1	p.R328M	9:133748322..133748322	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.R748G	PDGFRA	p.R748G	4:55146568..55146568	NCCN guidelines	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.R783G	ABL1	p.R783G	9:133759967..133759967	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.R841K	PDGFRA	p.R841K	4:55152090..55152090	PMID: 24132921	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S417F	ABL1	p.S417F	9:133750419..133750419	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S417Y	ABL1	p.S417Y	9:133750419..133750419	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S417Y	ABL1	p.S417Y	9:133750419..133750419	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S417Y	ABL1	p.S417Y	9:133750419..133750419	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S417Y	ABL1	p.S417Y	9:133750419..133750419	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S417Y	ABL1	p.S417Y	9:133750419..133750419	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S438C	ABL1	p.S438C	9:133753844..133753844	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S438C	ABL1	p.S438C	9:133753844..133753844	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.S438C	ABL1	p.S438C	9:133753844..133753844	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.S709F	KIT	p.S709F	4:55595648..55595648	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.S821F	KIT	p.S821F	4:55599336..55599336	PMID: 25735500	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T277A	ABL1	p.T277A	9:133747522..133747522	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T277A	ABL1	p.T277A	9:133747522..133747522	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T277A	ABL1	p.T277A	9:133747522..133747522	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315A	ABL1	p.T315A	9:133748282..133748282	PMID: 23223358	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 11853795	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 22489663	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 23355941	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315I	ABL1	p.T315I	9:133748283..133748283	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.T315N	ABL1	p.T315N	9:133748283..133748283	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670E	KIT	p.T670E	4:55595518..55595519	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670E	KIT	p.T670E	4:55595518..55595519	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 24687822	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 15930355	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 20028860	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.T670I	KIT	p.T670I	4:55595519..55595519	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA#p.T674I	PDGFRA	p.T674I	4:55144547..55144547	PMID: 12660384	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V256L	ABL1	p.V256L	9:133738366..133738366	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V280A	ABL1	p.V280A	9:133747532..133747532	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V289A	ABL1	p.V289A	9:133738409..133738409	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V289F	ABL1	p.V289F	9:133747558..133747558	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V289F	ABL1	p.V289F	9:133747558..133747558	PMID: 23355941	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V289F	ABL1	p.V289F	9:133747558..133747558	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V289I	ABL1	p.V289I	9:133747558..133747558	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 23086624	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V371A	ABL1	p.V371A	9:133750281..133750281	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V379I	ABL1	p.V379I	9:133750304..133750304	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V379I	ABL1	p.V379I	9:133750304..133750304	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V379I	ABL1	p.V379I	9:133750304..133750304	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V379I	ABL1	p.V379I	9:133750304..133750304	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V379I	ABL1	p.V379I	9:133750304..133750304	PMID: 26413254	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.V390L	ABL1	p.V390L	9:133750280..133750280	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V559A	KIT	p.V559A	4:55593610..55593610	PMID: 18066592	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V559A	KIT	p.V559A	4:55593610..55593610	PMID: 20736294	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V559D	KIT	p.V559D	4:55593610..55593610	PMID: 18066592	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V559I	KIT	p.V559I	4:55593609..55593609	PMID: 23582185, 21689725, 17259998	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 25182956	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V603D	KIT	p.V603D	4:55594022..55594022	.	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 23582185, 21689725, 17259998	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 15685537	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 15930355	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 17875769	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 18488000	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 18830121	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 23348204	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 23456621	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 25182956	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V654A	KIT	p.V654A	4:55594258..55594258	PMID: 26779618	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.W261L	ABL1	p.W261L	9:133738382..133738382	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.W557R	KIT	p.W557R	4:55593603..55593603	PMID: 18066592	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.W557R	KIT	p.W557R	4:55593603..55593603	PMID: 12960119	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 12623848	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253F	ABL1	p.Y253F	9:133738358..133738358	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 11853795	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 11964322	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 25281405	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 12399961	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 15381060	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 19567878	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 19625707	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 19768693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 19925053	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 20055659	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 20367437	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 20512393	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 20697894	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21239056	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21357704	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 22873741	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 23355941	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 23433665	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 23676790	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 23799845	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 24456693	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 26413254	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 12204532	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 14745431	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21156844	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21221851	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y253H	ABL1	p.Y253H	9:133738357..133738357	PMID: 21264552	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y320C	ABL1	p.Y320C	9:133748298..133748298	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y320C	ABL1	p.Y320C	9:133748298..133748298	PMID: 23053188	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y342H	ABL1	p.Y342H	9:133748363..133748363	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y353H	ABL1	p.Y353H	9:133748396..133748396	PMID: 21663510	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1#p.Y393C	ABL1	p.Y393C	9:133750347..133750347	PMID: 21562040	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y553N	KIT	p.Y553N	4:55593591..55593591	PMID: 21969494	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y553N	KIT	p.Y553N	4:55593591..55593591	PMID: 21969494	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	CSF1R#p.Y571D	CSF1R	p.Y571D	5:149441328..149441328	PMID: 18971950	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y578C	KIT	p.Y578C	4:55593667..55593667	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 23582185, 21689725, 17259998	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 15930355	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 16551858	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 16954519	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 17875769	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 18623623	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 20043176	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 23456621	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT::consequence::inframe_deletion:416-422,::inframe_insertion:416-422	KIT	KIT inframe deletion (416-422),inframe insertion (416-422)	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 15618474	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT::consequence::inframe_deletion:V560.	KIT	KIT inframe deletion (V560)	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 15201427	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 23099009	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	NF2:del	NF2	NF2 deletion	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 19509233, 2290085	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.D579del	KIT	p.D579 del	4:55593669..55593671	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.577_579del	KIT	p.P577_D579 del	4:55593663..55593671	PMID: 15201427	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.V560del	KIT	p.V560 del	4:55593612..55593614	PMID: 15201427	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT#p.569_578del	KIT	p.V569_Y578 del	4:55593639..55593668	PMID: 25886408	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	.	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA::consequence::inframe_deletion:I843.	PDGFRA	PDGFRA inframe deletion (I843)	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	NCCN guidelines	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	ABL1__BCR	ABL1	ABL1-BCR fusion	ABL1范围：9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12;BCR范围：22:23523097..23524436..exon1,23595975..23596177..exon2,23603126..23603251..exon3,23603531..23603737..exon4,23610584..23610712..exon5,23613708..23613789..exon6,23615257..23615330..exon7,23615810..23615971..exon8,23626153..23626295..exon9,23627209..23627398..exon10,23629335..23629475..exon11,23630273..23630369..exon12,23631693..23631818..exon13,23632515..23632610..exon14,23634717..23634835..exon15,23637200..23637352..exon16,23651600..23651680..exon17,23652500..23652630..exon18,23653873..23654033..exon19,23655063..23655218..exon20,23656144..23656270..exon21,23656728..23656911..exon22,23657609..23657759..exon23	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:627-664,664-714,449-514	KIT	KIT (627-664,664-714,449-514)	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18955458, 18955451, 16624552	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:D816.	KIT	KIT (D816)	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:amp	KIT	KIT amplification	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 23775962	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:788-828	KIT	KIT mutation in exon 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 23840364	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:788-828,829-860	KIT	KIT mutation in exon 17 or 18	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 21690468, 21642685	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:550-592,627-664	KIT	KIT mutation in exon 9,11,13,14 or 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	NCCN	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:550-592,627-664	KIT	KIT mutation in exon 9,11,13,14 or 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18421059, 21642685, 21690468, 22261812	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT:449-514,550-592,627-664,664-714,788-828	KIT	KIT mutation in exon 9,11,13,14 or 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	FDA	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KIT::wildtype:.	KIT	KIT wildtype	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	KRAS:G12.	KRAS	KRAS (G12)	12:25398283_25398285	PMID: 24687822	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 23099009	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	NF2:.	NF2	NF2 oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 19509233, 2290085	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFB__COL1A1	PDGFB	PDGFB-COL1A1 fusion	22:39621677..39621862..exon1,39626078..39626243..exon2,39627616..39627842..exon3,39629429..39629539..exon4,39631772..39631889..exon5,39636849..39636914..exon6,39639895..39640018..exon7	FDA	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA:552-596,631-668,814-854	PDGFRA	PDGFRA (552-596,631-668,814-854)	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	NCCN guidelines	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA__.	PDGFRA	PDGFRA fusion	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	EMA	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA::wildtype:.	PDGFRA	PDGFRA wildtype	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	PMID: 14645423, 18955458	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PDGFRA__FIP1L1	PDGFRA	PDGFRA-FIP1L1 fusion	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	EMA	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PRKCH:amp;ABL1__BCR	ABL1	PRKCH amplification + ABL1-BCR fusion	9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12	PMID: 25186176	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Imatinib	Imatinib (伊马替尼)	ABL;KIT;KIT	PRKCH:amp;ABL1__BCR	PRKCH	PRKCH amplification + ABL1-BCR fusion	14:61788769..61789192..exon1,61857932..61858016..exon2,61909818..61909989..exon3,61912399..61912454..exon4,61915871..61915980..exon5,61917549..61917699..exon6,61919933..61920081..exon7,61923883..61924047..exon8,61924213..61924407..exon9,61952209..61952384..exon10,61995782..61995941..exon11,61997114..61997323..exon12,62014450..62014614..exon13,62016392..62016599..exon14;ABL1范围：9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12;BCR范围：22:23523097..23524436..exon1,23595975..23596177..exon2,23603126..23603251..exon3,23603531..23603737..exon4,23610584..23610712..exon5,23613708..23613789..exon6,23615257..23615330..exon7,23615810..23615971..exon8,23626153..23626295..exon9,23627209..23627398..exon10,23629335..23629475..exon11,23630273..23630369..exon12,23631693..23631818..exon13,23632515..23632610..exon14,23634717..23634835..exon15,23637200..23637352..exon16,23651600..23651680..exon17,23652500..23652630..exon18,23653873..23654033..exon19,23655063..23655218..exon20,23656144..23656270..exon21,23656728..23656911..exon22,23657609..23657759..exon23	PMID: 25186176	NCT00764595:Phase 2:Completed:No publish||NCT00025415:Phase 1:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	白血病; 皮肤纤维肉瘤; 胃肠道间质瘤	II
Ipilimumab	Ipilimumab (易普利姆玛)	IgG1 	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 22382362, 23709751	NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish||NCT03203304:Phase 1:Recruiting:No publish||NCT03222076:Phase 2:Recruiting:No publish	否	否	敏感性增加;药物可引起严重和致死性的免疫调节副作用	黑色素瘤	III
Ipilimumab	Ipilimumab (易普利姆玛)	IgG1 	BRAF#p.V600K	BRAF	p.V600K	7:140453136..140453137	PMID: 22382362, 23709751	NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish||NCT03203304:Phase 1:Recruiting:No publish||NCT03222076:Phase 2:Recruiting:No publish	否	否	敏感性增加;药物可引起严重和致死性的免疫调节副作用	黑色素瘤	III
Ipilimumab	Ipilimumab (易普利姆玛)	IgG1 	BRAF#p.V600R	BRAF	p.V600R	7:140453136..140453137	PMID: 22382362, 23709751	NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish||NCT03203304:Phase 1:Recruiting:No publish||NCT03222076:Phase 2:Recruiting:No publish	否	否	敏感性增加;药物可引起严重和致死性的免疫调节副作用	黑色素瘤	III
Irinotecan	Irinotecan	TOP1	RAD50:L1237F;ATM:del	ATM	RAD50 (L1237F) + ATM deletion	11:108098301..108098433..exon1,108098492..108098625..exon2,108099894..108100060..exon3,108106386..108106571..exon4,108114669..108114855..exon5,108115504..108115763..exon6,108117680..108117864..exon7,108119649..108119839..exon8,108121417..108121809..exon9,108122553..108122768..exon10,108123533..108123649..exon11,108124530..108124776..exon12,108126931..108127077..exon13,108128197..108128343..exon14,108129702..108129812..exon15,108137887..108138079..exon16,108139126..108139346..exon17,108141780..108141883..exon18,108141967..108142143..exon19,108143248..108143344..exon20,108143438..108143589..exon21,108150207..108150345..exon22,108151711..108151905..exon23,108153426..108153616..exon24,108154943..108155210..exon25,108158316..108158452..exon26,108159693..108159840..exon27,108160318..108160538..exon28,108163335..108163530..exon29,108164029..108164214..exon30,108165643..108165796..exon31,108168003..108168119..exon32,108170430..108170622..exon33,108172364..108172526..exon34,108173569..108173766..exon35,108175391..108175589..exon36,108178613..108178721..exon37,108180876..108181052..exon38,108183127..108183235..exon39,108186539..108186648..exon40,108186727..108186850..exon41,108188089..108188258..exon42,108190670..108190795..exon43,108192017..108192157..exon44,108196026..108196281..exon45,108196774..108196962..exon46,108198361..108198495..exon47,108199737..108199975..exon48,108200930..108201158..exon49,108202160..108202294..exon50,108202595..108202774..exon51,108203478..108203637..exon52,108204602..108204705..exon53,108205685..108205846..exon54,108206561..108206698..exon55,108213938..108214108..exon56,108216459..108216645..exon57,108217995..108218102..exon58,108224482..108224617..exon59,108225527..108225611..exon60,108235798..108235955..exon61,108236041..108236285..exon62	PMID: 24934408	NCT00087282:Phase 2:Completed:No publish||NCT00287976:Phase 2:Unknown status:No publish||NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.||NCT00980239:Phase 1:Completed:No publish||NCT03533582:Phase 2|Phase 3:Recruiting:No publish||NCT00143403:Phase 3:Completed:No publish||NCT00537121:Phase 1:Completed:No publish||NCT00980460:Phase 3:Active, not recruiting:No publish||NCT00020501:Phase 3:Completed:No publish||NCT00654160:Phase 1:Completed:No publish||NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.||NCT00031681:Phase 1:Completed:No publish||NCT01643499:Phase 1:Active, not recruiting:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT03493061:Phase 2:Recruiting:No publish||NCT00101270:Phase 1:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.||NCT03017326:Phase 3:Recruiting:No publish||NCT00635323:Phase 2:Completed:No publish||NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.||NCT00408551:Phase 2:Unknown status:No publish||NCT01226719:Phase 2:Completed:No publish||NCT00513266:Phase 2:Unknown status:No publish||NCT00023868:Phase 3:Completed:No publish||NCT03069950:Phase 2:Recruiting:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT00063960:Phase 2:Completed:No publish||NCT00557102:Phase 2:Completed:No publish||NCT00003368:Phase 1:Completed:Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.||NCT00003753:Phase 2:Completed:No publish||NCT00492999:Phase 2:Active, not recruiting:No publish||NCT00037804:Phase 1:Completed:No publish||NCT00030563:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	晚期胰腺癌	II
Irinotecan	Irinotecan	TOP1	RAD50:L1237F;ATM:del	RAD50	RAD50 (L1237F) + ATM deletion	5:131892966..131893155..exon1,131894965..131895069..exon2,131911458..131911630..exon3,131914998..131915204..exon4,131915543..131915768..exon5,131923243..131923392..exon6,131923605..131923791..exon7,131924368..131924582..exon8,131925312..131925539..exon9,131926905..131927108..exon10,131927558..131927736..exon11,131930550..131930746..exon12,131931254..131931512..exon13,131938981..131939191..exon14,131939601..131939748..exon15,131940487..131940701..exon16,131944296..131944427..exon17,131944798..131944911..exon18,131944964..131945098..exon19,131951684..131951832..exon20,131953751..131953996..exon21,131972796..131972902..exon22,131973762..131973925..exon23,131976353..131976507..exon24,131977859..131978106..exon25	PMID: 24934408	NCT00087282:Phase 2:Completed:No publish||NCT00287976:Phase 2:Unknown status:No publish||NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.||NCT00980239:Phase 1:Completed:No publish||NCT03533582:Phase 2|Phase 3:Recruiting:No publish||NCT00143403:Phase 3:Completed:No publish||NCT00537121:Phase 1:Completed:No publish||NCT00980460:Phase 3:Active, not recruiting:No publish||NCT00020501:Phase 3:Completed:No publish||NCT00654160:Phase 1:Completed:No publish||NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.||NCT00031681:Phase 1:Completed:No publish||NCT01643499:Phase 1:Active, not recruiting:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT03493061:Phase 2:Recruiting:No publish||NCT00101270:Phase 1:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.||NCT03017326:Phase 3:Recruiting:No publish||NCT00635323:Phase 2:Completed:No publish||NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.||NCT00408551:Phase 2:Unknown status:No publish||NCT01226719:Phase 2:Completed:No publish||NCT00513266:Phase 2:Unknown status:No publish||NCT00023868:Phase 3:Completed:No publish||NCT03069950:Phase 2:Recruiting:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT00063960:Phase 2:Completed:No publish||NCT00557102:Phase 2:Completed:No publish||NCT00003368:Phase 1:Completed:Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.||NCT00003753:Phase 2:Completed:No publish||NCT00492999:Phase 2:Active, not recruiting:No publish||NCT00037804:Phase 1:Completed:No publish||NCT00030563:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	晚期胰腺癌	II
Irinotecan	Irinotecan	TOP1	BRAF:V600.	BRAF	BRAF p.V600	7:140453136..140453137	PMID: 27729313	NCT00087282:Phase 2:Completed:No publish||NCT00287976:Phase 2:Unknown status:No publish||NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.||NCT00980239:Phase 1:Completed:No publish||NCT03533582:Phase 2|Phase 3:Recruiting:No publish||NCT00143403:Phase 3:Completed:No publish||NCT00537121:Phase 1:Completed:No publish||NCT00980460:Phase 3:Active, not recruiting:No publish||NCT00020501:Phase 3:Completed:No publish||NCT00654160:Phase 1:Completed:No publish||NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.||NCT00031681:Phase 1:Completed:No publish||NCT01643499:Phase 1:Active, not recruiting:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT03493061:Phase 2:Recruiting:No publish||NCT00101270:Phase 1:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.||NCT03017326:Phase 3:Recruiting:No publish||NCT00635323:Phase 2:Completed:No publish||NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.||NCT00408551:Phase 2:Unknown status:No publish||NCT01226719:Phase 2:Completed:No publish||NCT00513266:Phase 2:Unknown status:No publish||NCT00023868:Phase 3:Completed:No publish||NCT03069950:Phase 2:Recruiting:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT00063960:Phase 2:Completed:No publish||NCT00557102:Phase 2:Completed:No publish||NCT00003368:Phase 1:Completed:Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.||NCT00003753:Phase 2:Completed:No publish||NCT00492999:Phase 2:Active, not recruiting:No publish||NCT00037804:Phase 1:Completed:No publish||NCT00030563:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	晚期胰腺癌	II
Irinotecan	Irinotecan	TOP1	UGT1A1:.	UGT1A1	UGT1A1 biallelic inactivation	2:234668918..234669807..exon1,234675669..234675821..exon2,234676484..234676592..exon3,234676855..234677095..exon4,234680897..234681255..exon5	.	NCT00087282:Phase 2:Completed:No publish||NCT00287976:Phase 2:Unknown status:No publish||NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.||NCT00980239:Phase 1:Completed:No publish||NCT03533582:Phase 2|Phase 3:Recruiting:No publish||NCT00143403:Phase 3:Completed:No publish||NCT00537121:Phase 1:Completed:No publish||NCT00980460:Phase 3:Active, not recruiting:No publish||NCT00020501:Phase 3:Completed:No publish||NCT00654160:Phase 1:Completed:No publish||NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.||NCT00031681:Phase 1:Completed:No publish||NCT01643499:Phase 1:Active, not recruiting:No publish||NCT03493048:Phase 2:Recruiting:No publish||NCT03493061:Phase 2:Recruiting:No publish||NCT00101270:Phase 1:Completed:No publish||NCT01442935:Phase 2:Active, not recruiting:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.||NCT03017326:Phase 3:Recruiting:No publish||NCT00635323:Phase 2:Completed:No publish||NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.||NCT00408551:Phase 2:Unknown status:No publish||NCT01226719:Phase 2:Completed:No publish||NCT00513266:Phase 2:Unknown status:No publish||NCT00023868:Phase 3:Completed:No publish||NCT03069950:Phase 2:Recruiting:No publish||NCT01802645:Phase 2:Recruiting:No publish||NCT00063960:Phase 2:Completed:No publish||NCT00557102:Phase 2:Completed:No publish||NCT00003368:Phase 1:Completed:Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.||NCT00003753:Phase 2:Completed:No publish||NCT00492999:Phase 2:Active, not recruiting:No publish||NCT00037804:Phase 1:Completed:No publish||NCT00030563:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	毒性增加	晚期胰腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.D769H	ERBB2	p.D769H	17:37880261..37880261	PMID: 23220880	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.D769Y	ERBB2	p.D769Y	17:37880261..37880261	PMID: 23220880	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB4#p.E317K	ERBB4	p.E317K	2:212578308..212578308	PMID: 19718025	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB4#p.E452K	ERBB4	p.E452K	2:212566827..212566827	PMID: 19718025	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.E690K	EGFR	p.E690K	7:55241620..55241620	PMID: 22885469	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB4#p.E872K	ERBB4	p.E872K	2:212295699..212295699	PMID: 19718025	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB3#p.G284R	ERBB3	p.G284R	12:56481922..56481922	PMID: 23680147	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.G309A	ERBB2	p.G309A	17:37868205..37868205	PMID: 23220880	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.G719A	EGFR	p.G719A	7:55241708..55241708	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.G719D	EGFR	p.G719D	7:55241708..55241708	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.G721V	EGFR	p.G721V	7:55241714..55241714	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB4#p.H809G	ERBB4	p.H809G	2:212426689..212426690delTnsCC	PMID: 26530965	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.I789M	EGFR	p.I789M	7:55249069..55249069	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.K716R	EGFR	p.K716R	7:55241699..55241699	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.K753E	ERBB2	p.K753E	17:37880213..37880213	PMID: 27697991	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.N842H	EGFR	p.N842H	7:55259466..55259466	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB3#p.P262H	ERBB3	p.P262H	12:56481857..56481857	PMID: 23680147	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB3#p.Q809R	ERBB3	p.Q809R	12:56490980..56490980	PMID: 23680147	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB4#p.R393W	ERBB4	p.R393W	2:212570064..212570064	PMID: 19718025	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB4#p.R544W	ERBB4	p.R544W	2:212537975..212537975	PMID: 19718025	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.R896C	ERBB2	p.R896C	17:37881616..37881616	PMID: 23220880	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.S720C	EGFR	p.S720C	7:55241711..55241711	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.V659E	ERBB2	p.V659E	17:37879601..37879602	PMID: 23950206	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.V742I	EGFR	p.V742I	7:55242454..55242454	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.V769L	EGFR	p.V769L	7:55249007..55249007	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.V774M	EGFR	p.V774M	7:55249022..55249022	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.V777L	ERBB2	p.V777L	17:37881000..37881000	PMID: 23220880	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2#p.V842I	ERBB2	p.V842I	17:37881332..37881332	PMID: 23220880	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	NF2:del	NF2	NF2 deletion	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 22844108;NCT00973739	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.771in_frame_insSVD	EGFR	p.771in_frame_insSVD	7:55249148..55249150	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	EGFR#p.ELREA746in_frame_del	EGFR	p.ELREA746in_frame_ del	7:55249073..55249075	.	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	FDA	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26022204	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 25694417;NCT02015169	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 25294905	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2:over	ERBB2	ERBB2 overexpression	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	FDA	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547;ASCO 2017 (abstr 9071)	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	ERBB4__.	ERBB4	ERBB4 fusion	2:212248289..212248795..exon1,212251567..212251885..exon2,212252659..212252727..exon3,212285155..212285346..exon4,212286721..212286839..exon5,212288869..212289036..exon6,212293122..212293218..exon7,212295659..212295835..exon8,212426617..212426823..exon9,212483891..212484010..exon10,212488636..212488779..exon11,212495176..212495329..exon12,212522468..212522563..exon13,212530037..212530212..exon14,212537878..212537992..exon15,212543766..212543919..exon16,212566681..212566901..exon17,212568818..212568929..exon18,212570032..212570126..exon19,212576764..212576911..exon20,212578249..212578383..exon21,212587107..212587269..exon22,212589790..212589929..exon23,212615353..212615439..exon24,212652739..212652894..exon25,212812144..212812351..exon26,212989466..212989638..exon27,213403162..213403304..exon28	PMID: 24727320	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	MET:amp;ERBB2:amp	ERBB2	MET amplification + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 22238368	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	MET:amp;ERBB2:amp	MET	MET amplification + ERBB2 amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 22238368	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	NF2:.	NF2	NF2 oncogenic mutation	22:29999937..30000111..exon1,30032729..30032875..exon2,30035068..30035211..exon3,30038180..30038284..exon4,30050635..30050724..exon5,30051572..30051675..exon6,30054167..30054263..exon7,30057183..30057338..exon8,30060968..30061063..exon9,30064311..30064445..exon10,30067804..30067947..exon11,30069247..30069485..exon12,30070814..30070940..exon13,30074174..30074322..exon14,30077417..30077600..exon15,30078998..30079094..exon16,30090730..30090841..exon17	PMID: 22844108;NCT00973739	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
Lapatinib	Lapatinib (拉帕替尼)	EGFR;ERBB2	NRG1__.	NRG1	NRG1 fusion	8:31497450..31498255..exon1,32406194..32406354..exon2,32453335..32453533..exon3,32463069..32463211..exon4,32472021..32472092..exon5,32474342..32474413..exon6,32505186..32505913..exon7,32579470..32579570..exon8,32585456..32585606..exon9,32585456..32585650..exon10,32599515..32599603..exon11,32600182..32600261..exon12,32600182..32600336..exon13,32607068..32607112..exon14,32611879..32612002..exon15,32611913..32612002..exon16,32613910..32614057..exon17,32616813..32616964..exon18,32617707..32617934..exon19,32617707..32617978..exon20,32620725..32620906..exon21,32621255..32621970..exon22	PMID: 24727320	NCT00101036:Phase 2:Completed:No publish||NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.||NCT02015169:Phase 2:Completed:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	乳腺癌	II
MK2206	MK2206	AKT	AKT2:amp	AKT2	AKT2 amplification	19:40739728..40739868..exon1,40740941..40741064..exon2,40741159..40741267..exon3,40741786..40742021..exon4,40742153..40742302..exon5,40743865..40744008..exon6,40744801..40744890..exon7,40745941..40746027..exon8,40747834..40747986..exon9,40748430..40748604..exon10,40761054..40761186..exon11,40761054..40761215..exon12,40762822..40762971..exon13,40771118..40771224..exon14	ENA 2014 (abstr 373)	NCT01425879:Phase 2:Completed:No publish	否	否	敏感性增加	乳腺癌	III
MK2206	MK2206	AKT	ERBB2:over	ERBB2	ERBB2 overexpression	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	ASCO 2013 (abstr 2605), 26104654	NCT01425879:Phase 2:Completed:No publish	否	否	敏感性增加	乳腺癌	III
MK2206	MK2206	AKT	HER2 amplification	HER2	HER2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 20453058, 23714559	NCT01425879:Phase 2:Completed:No publish	否	否	敏感性增加	乳腺癌	III
MK2206	MK2206	AKT	PI3KCA oncogenic mutation	PIK3CA	PI3KCA oncogenic mutation	3:178916563..178916975..exon1,178917467..178917697..exon2,178919067..178919338..exon3,178921321..178921587..exon4,178922280..178922386..exon5,178927372..178927498..exon6,178927963..178928136..exon7,178928208..178928363..exon8,178935987..178936132..exon9,178936973..178937075..exon10,178937348..178937533..exon11,178937726..178937850..exon12,178938763..178938955..exon13,178941858..178941985..exon14,178942477..178942619..exon15,178943739..178943838..exon16,178947049..178947240..exon17,178947781..178947919..exon18,178948002..178948174..exon19,178951871..178952202..exon20	PMID: 22932669, 23714559	NCT01425879:Phase 2:Completed:No publish	否	否	敏感性增加	乳腺癌	III
MK2206	MK2206	AKT	PI3KCA oncogenic mutation	PIK3CA	PI3KCA oncogenic mutation	3:178916563..178916975..exon1,178917467..178917697..exon2,178919067..178919338..exon3,178921321..178921587..exon4,178922280..178922386..exon5,178927372..178927498..exon6,178927963..178928136..exon7,178928208..178928363..exon8,178935987..178936132..exon9,178936973..178937075..exon10,178937348..178937533..exon11,178937726..178937850..exon12,178938763..178938955..exon13,178941858..178941985..exon14,178942477..178942619..exon15,178943739..178943838..exon16,178947049..178947240..exon17,178947781..178947919..exon18,178948002..178948174..exon19,178951871..178952202..exon20	PMID: 20453058, 23714559	NCT01425879:Phase 2:Completed:No publish	否	否	敏感性增加	乳腺癌	III
MK2206	MK2206	AKT	PTEN loss (Loss of PTEN activity)	PTEN	PTEN loss (Loss of PTEN activity)	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	PMID: 22932669, 23714559	NCT01425879:Phase 2:Completed:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.D769H	ERBB2	p.D769H	17:37880261..37880261	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.D769Y	ERBB2	p.D769Y	17:37880261..37880261	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.G309A	ERBB2	p.G309A	17:37868205..37868205	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.K753E	ERBB2	p.K753E	17:37880213..37880213	PMID: 27697991	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.L755S	ERBB2	p.L755S	17:37880220..37880220	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.R896C	ERBB2	p.R896C	17:37881616..37881616	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.V777L	ERBB2	p.V777L	17:37881000..37881000	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2#p.V842I	ERBB2	p.V842I	17:37881332..37881332	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2::consequence::inframe_deletion:755-759,::inframe_insertion:.780GSP,::inframe_insertion:.781GSP	ERBB2	ERBB2 inframe deletion (755-759),inframe insertion (780GSP),inframe insertion (781GSP)	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 23220880	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2::consequence::inframe_insertion:P780GSP,::inframe_insertion:.781GSP,::inframe_insertion:A775YVMA,::inframe_insertion:G776YVMA	ERBB2	ERBB2 inframe insertion (P780GSP),inframe insertion (781GSP),inframe insertion (A775YVMA),inframe insertion (G776YVMA)	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	AACR 2017 (abstr CT001)	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2:S310.,L755.,V777.	ERBB2	ERBB2 (S310,L755,V777)	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	AACR 2017 (abstr CT001)	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 20142587, 22418700, 23632474	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2:.	ERBB2	ERBB2 oncogenic mutation	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	ESMO 2014 (abstr LBA39_PR)	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Neratinib	Neratinib (来那替尼)	ERBB2	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547;ASCO 2017 (abstr 9071)	NCT01953926:Phase 2:Recruiting:No publish	否	否	敏感性增加	乳腺癌	III
Nintedanib	Nintedanib	KIT; PDGFR; RAF; RET; VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	RET__.	RET	RET fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 26787234	NCT01594125:Phase 1:Completed:No publish||NCT01594125:Phase 1:Completed:No publish||NCT01594125:Phase 1:Completed:No publish	是（非本癌种）	否	敏感性增加	特发性肺纤维化（IPF）	III
Osimertinib	Osimertinib (奥希替尼)	EGFR	EGFR#p.L858R	EGFR	p.L858R	7:55259515..55259515	NCT02465060	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Osimertinib	Osimertinib (奥希替尼)	EGFR	EGFR#p.T790M	EGFR	p.T790M	7:55249071..55249071	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Osimertinib	Osimertinib (奥希替尼)	EGFR	EGFR::consequence::inframe_deletion:729-761	EGFR	EGFR exon 19 deletions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	NCT02465060	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Osimertinib	Osimertinib (奥希替尼)	EGFR	EGFR::consequence::inframe_insertion:762-823	EGFR	EGFR exon 20 insertions	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	PMID: 26515464	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Osimertinib	Osimertinib (奥希替尼)	EGFR	EGFR:L718.	EGFR	EGFR (L718)	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	ASCO 2017 (abstr 2572)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Osimertinib	Osimertinib (奥希替尼)	EGFR	EGFR:L792.	EGFR	EGFR (L792)	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	ASCO 2017 (abstr 2572)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Osimertinib	Osimertinib (奥希替尼)	EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 27252416	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Osimertinib	Osimertinib (奥希替尼)	EGFR	MET:amp	MET	MET amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 27252416	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加;少数案例中发生胚胎毒性和心肌病	肺癌	II
Palbociclib	Palbociclib (帕博西尼)	CDK4;CDK6	CCND1:amp	CCND1	CCND1 amplification	11:69456031..69456289..exon1,69457788..69458024..exon2,69458589..69458769..exon3,69462751..69462920..exon4,69465875..69466100..exon5	ASCO 2017 (abstr 9056)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性降低	乳腺癌	II
Palbociclib	Palbociclib (帕博西尼)	CDK4;CDK6	CCND2:amp	CCND2	CCND2 amplification	12:4383156..4383411..exon1,4385160..4385396..exon2,4387915..4388095..exon3,4397997..4398166..exon4,4409015..4409225..exon5	NCT02154490	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌	II
Palbociclib	Palbociclib (帕博西尼)	CDK4;CDK6	CDK4:amp	CDK4	CDK4 amplification	12:58142257..58142410..exon1,58142954..58143110..exon2,58143226..58143297..exon3,58144428..58144558..exon4,58144695..58144883..exon5,58144979..58145135..exon6,58145272..58145550..exon7	ASCO 2017 (abstr 9056)	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性降低	乳腺癌	II
Palbociclib	Palbociclib (帕博西尼)	CDK4;CDK6	CDKN2A: inactivating mutation	CDKN2A	CDKN2A: inactivating mutation	9:21968177..21968251..exon1,21968673..21968780..exon2,21970890..21971217..exon3,21970951..21971217..exon4,21974425..21974836..exon5,21974666..21974876..exon6,21994127..21994380..exon7	PMID:  29487225	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌	II
Palbociclib	Palbociclib (帕博西尼)	CDK4;CDK6	ERBB2:norm;ESR1:over	ERBB2	ERBB2 expression + ESR1 overexpression	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌	II
Palbociclib	Palbociclib (帕博西尼)	CDK4;CDK6	ERBB2:norm;ESR1:over	ESR1	ERBB2 expression + ESR1 overexpression	6:152128997..152129509..exon1,152163721..152163932..exon2,152163721..152163938..exon3,152163748..152163932..exon4,152201779..152201913..exon5,152201779..152201916..exon6,152265297..152265653..exon7,152332780..152332939..exon8,152382115..152382269..exon9,152415509..152415713..exon10,152419856..152420151..exon11,152446390..152446533..exon12	FDA	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌	II
Palbociclib	Palbociclib (帕博西尼)	CDK4;CDK6	RB1:over	RB1	RB1 overexpression	13:48877998..48878195..exon1,48881405..48881552..exon2,48916724..48916860..exon3,48919205..48919345..exon4,48921950..48922009..exon5,48923081..48923169..exon6,48934142..48934273..exon7,48936940..48937103..exon8,48939019..48939117..exon9,48941619..48941749..exon10,48942652..48942750..exon11,48947530..48947638..exon12,48951043..48951180..exon13,48953719..48953796..exon14,48954178..48954230..exon15,48954290..48954387..exon16,48955372..48955589..exon17,49027118..49027257..exon18,49030329..49030495..exon19,49033813..49033979..exon20,49037856..49037981..exon21,49039123..49039257..exon22,49039330..49039514..exon23,49047485..49047536..exon24,49050826..49050989..exon25,49051480..49051550..exon26,49054123..49054257..exon27	PMID: 23708653	NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	EGFR#p.G465R	EGFR	p.G465R	7:55227926..55227926	PMID: 26059438	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	EGFR#p.S492R	EGFR	p.S492R	7:55228009..55228009	PMID: 22270724	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 3:Recruiting:No publish	是（非本癌种）	否	敏感性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 20619739, 21163703, 23325582	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 4:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	BRAF:V600.	BRAF	BRAF p.V600	7:140453136..140453137	ENA 2014 (abstr 11LBA)	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 5:Recruiting:No publish	是（非本癌种）	否	敏感性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	EGFR:over	EGFR	EGFR overexpression	7:55086920..55087068..exon1,55209968..55210140..exon2,55209999..55210140..exon3,55210987..55211191..exon4,55214288..55214443..exon5,55218976..55219065..exon6,55220228..55220367..exon7,55221693..55221855..exon8,55223512..55223649..exon9,55224215..55224362..exon10,55224441..55224535..exon11,55224441..55224586..exon12,55225345..55225456..exon13,55227821..55228041..exon14,55229181..55229334..exon15,55231415..55231526..exon16,55232962..55233140..exon17,55236205..55236272..exon18,55237989..55238287..exon19,55238857..55238916..exon20,55240665..55240827..exon21,55241603..55241746..exon22,55242404..55242523..exon23,55248975..55249181..exon24,55259401..55259577..exon25,55260448..55260544..exon26,55266399..55266566..exon27,55267998..55268116..exon28,55268870..55269058..exon29,55269417..55269485..exon30,55270199..55270328..exon31,55270199..55270508..exon32,55272938..55273360..exon33	FDA guidelines	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 6:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	FDA guidelines	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 7:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	MET:amp	MET	MET amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	ENA 2015 (abstr A52)	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 8:Recruiting:No publish	是（非本癌种）	否	敏感性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	MET:amp;BRAF:V600E	MET	MET amplification + BRAF (V600E)	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 27325282	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 9:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	MET:amp;BRAF:V600E	BRAF	MET amplification + BRAF (V600E)	7:140434346..140434580..exon1,140439601..140439756..exon2,140449076..140449228..exon3,140453064..140453203..exon4,140453976..140454043..exon5,140476701..140476898..exon6,140477780..140477885..exon7,140481365..140481503..exon8,140482810..140482967..exon9,140487337..140487394..exon10,140494097..140494277..exon11,140500151..140500291..exon12,140501201..140501370..exon13,140507749..140507872..exon14,140508681..140508805..exon15,140534398..140534682..exon16,140549900..140550022..exon17,140624355..140624553..exon18	PMID: 27325282	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 10:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	NRAS:.	NRAS	NRAS oncogenic mutation	1:115251105..115251285..exon1,115252179..115252359..exon2,115256410..115256609..exon3,115258660..115258831..exon4	PMID: 24024839, 20619739, 23325582	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 11:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Panitumumab	Panitumumab (帕尼单抗)	IgG2 ;EGFR	PTEN:.	PTEN	PTEN biallelic inactivation	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	Caris molecular intelligence	NCT01384994:Phase 2:Unknown status:No publish||NCT03366155:Phase 2:Not yet recruiting:No publish||NCT01226719:Phase 2:Completed:No publish||NCT02885753:Phase 3:Recruiting:No publish||NCT03069950:Phase 12:Recruiting:No publish	是（非本癌种）	否	耐药性增加	结直肠癌	II
Pazopanib	Pazopanib (培唑帕尼)	KIT; PDGFR; RAF; RET; VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24931142	NCT00370513:Phase 1:Completed:No publish||NCT00674024:Phase 1:Completed:No publish||NCT00674024:Phase 1:Completed:No publish	是（非本癌种）	否	敏感性增加	软组织肉瘤; 肾癌	II
Pazopanib	Pazopanib (培唑帕尼)	KIT; PDGFR; RAF; RET; VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	UGT1A1:.	UGT1A1	UGT1A1 biallelic inactivation	2:234668918..234669807..exon1,234675669..234675821..exon2,234676484..234676592..exon3,234676855..234677095..exon4,234680897..234681255..exon5	FDA	NCT00370513:Phase 1:Completed:No publish||NCT00674024:Phase 1:Completed:No publish||NCT00674024:Phase 1:Completed:No publish	是（非本癌种）	否	毒性增加	软组织肉瘤; 肾癌	II
Pembrolizumab	Pembrolizumab (派姆单抗)	PD-1	CD274:over	CD274	CD274 overexpression	9:5456063..5456175..exon1,5457068..5457430..exon2,5462823..5463131..exon3,5462823..5463227..exon4,5465488..5465616..exon5,5466759..5466839..exon6,5467829..5467912..exon7	NCT01848834;The ASCO Post. 2018 GI CANCERS SYMPOSIUM: KEYNOTE-224 Trial: Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib	NCT03397654:Phase 1|Phase 2:Not yet recruiting:No publish||NCT02509507:Phase 1:Recruiting:No publish||NCT02940496:Phase 1|Phase 2:Recruiting:No publish||NCT03347292:Phase 1:Recruiting:No publish||NCT03511222:Phase 1:Not yet recruiting:No publish||NCT01174121:Phase 2:Recruiting:No publish||NCT03519997:Phase 2:Recruiting:No publish||NCT03337841:Phase 2:Not yet recruiting:No publish||NCT03163992:Phase 2:Recruiting:No publish||NCT03006926:Phase 1:Recruiting:No publish||NCT03419481:Phase 2:Recruiting:No publish||NCT02658019:Phase 2:Active, not recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加;晚期肝癌患者若是服用索拉非尼后疾病继续恶化，再改用Pembrolizumab的话，其中94%的患者能够缓解病情超过6个月	膀胱癌; 非小细胞肺癌; 黑色素瘤; 淋巴瘤; 头颈癌;用于治疗不可切除或转移黑色素瘤；高PD-L1表达且EGFR\ALK未检测到突变，未进行化疗的非小细胞肺癌或EGFR/ALK突变疾病进展的非小细胞肺癌；已经获批用于MSI-H或dMMR的实体瘤患者	I
Selumetinib	Selumetinib	MEK1;MEK2	HRAS#p.G12R	HRAS	p.G12R	11:534289..534289	PMID: 23406027, 21526955	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	HRAS#p.G12V	HRAS	p.G12V	11:534288..534288	PMID: 23406027, 21526955	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	HRAS#p.G13C	HRAS	p.G13C	11:534286..534286	PMID: 23406027, 21526955	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	HRAS#p.G13R	HRAS	p.G13R	11:534286..534286	PMID: 23406027, 21526955	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	GNA11#p.Q209L	GNA11	p.Q209L	19:3118942..3118942	ASCO 2013 (abstr CRA9003)	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	GNAQ#p.Q209L	GNAQ	p.Q209L	9:80409488..80409488	ASCO 2013 (abstr CRA9003)	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	GNA11#p.Q209P	GNA11	p.Q209P	19:3118942..3118942	ASCO 2013 (abstr CRA9003)	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	NRAS#p.Q61K	NRAS	p.Q61K	1:115256530..115256530	PMID: 22194965	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	HRAS#p.Q61R	HRAS	p.Q61R	11:533874..533874	PMID: 23406027, 21526955	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	NCT01089101	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	MAP2K1::consequence::inframe_deletion:56-60	MAP2K1	MAP2K1 inframe deletion (56-60)	15:66679635..66679775..exon1,66727354..66727585..exon2,66729073..66729240..exon3,66735607..66735705..exon4,66736983..66737055..exon5,66774082..66774227..exon6,66777317..66777539..exon7,66779555..66779640..exon8,66781542..66781624..exon9,66782045..66782111..exon10,66782829..66783003..exon11	PMID: 26324360	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	ASCO 2014 (abstr 10018)	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	NF1:del;BRAF:.	NF1	NF1 deletion + BRAF oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 23444215	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	耐药性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	NF1:del;BRAF:.	BRAF	NF1 deletion + BRAF oncogenic mutation	7:140434346..140434580..exon1,140439601..140439756..exon2,140449076..140449228..exon3,140453064..140453203..exon4,140453976..140454043..exon5,140476701..140476898..exon6,140477780..140477885..exon7,140481365..140481503..exon8,140482810..140482967..exon9,140487337..140487394..exon10,140494097..140494277..exon11,140500151..140500291..exon12,140501201..140501370..exon13,140507749..140507872..exon14,140508681..140508805..exon15,140534398..140534682..exon16,140549900..140550022..exon17,140624355..140624553..exon18	PMID: 23444215	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	耐药性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	BRAF__.	BRAF	BRAF fusion	7:140434346..140434580..exon1,140439601..140439756..exon2,140449076..140449228..exon3,140453064..140453203..exon4,140453976..140454043..exon5,140476701..140476898..exon6,140477780..140477885..exon7,140481365..140481503..exon8,140482810..140482967..exon9,140487337..140487394..exon10,140494097..140494277..exon11,140500151..140500291..exon12,140501201..140501370..exon13,140507749..140507872..exon14,140508681..140508805..exon15,140534398..140534682..exon16,140549900..140550022..exon17,140624355..140624553..exon18	PMID: 26324360	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	NCT00890825	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	PMID: 26802155	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性降低	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	ASCO 2014 (abstr 10018)	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	敏感性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	NF1:.;BRAF:.	NF1	NF1 oncogenic mutation + BRAF oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 23444215	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	耐药性增加	非小细胞肺癌;小细胞肺癌	II
Selumetinib	Selumetinib	MEK1;MEK2	NF1:.;BRAF:.	BRAF	NF1 oncogenic mutation + BRAF oncogenic mutation	7:140434346..140434580..exon1,140439601..140439756..exon2,140449076..140449228..exon3,140453064..140453203..exon4,140453976..140454043..exon5,140476701..140476898..exon6,140477780..140477885..exon7,140481365..140481503..exon8,140482810..140482967..exon9,140487337..140487394..exon10,140494097..140494277..exon11,140500151..140500291..exon12,140501201..140501370..exon13,140507749..140507872..exon14,140508681..140508805..exon15,140534398..140534682..exon16,140549900..140550022..exon17,140624355..140624553..exon18	PMID: 23444215	NCT00604721:Phase 2:Completed:No publish||NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	否	否	耐药性增加	非小细胞肺癌;小细胞肺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	RET#p.C634W	RET	p.C634W	10:43609950..43609950	PMID: 21470995	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	FLT3#p.D835Y	FLT3	p.D835Y	13:28592642..28592642	PMID: 23969938	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 22718859, 16638875	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PDGFRA#p.D842V	PDGFRA	p.D842V	4:55152093..55152093	PMID: 25735500	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.E490K	KIT	p.E490K	4:55592144..55592144	PMID: 21325067	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.G812V	KIT	p.G812V	4:55599309..55599309	.	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.H697Y	KIT	p.H697Y	4:55595599..55595599	PMID: 19861435	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.H697Y	KIT	p.H697Y	4:55595599..55595599	PMID: 19861435	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.I571K	KIT	p.I571K	4:55593646..55593646	.	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.K642E	KIT	p.K642E	4:55594221..55594221	PMID: 22261812	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.L576P	KIT	p.L576P	4:55593661..55593661	PMID: 22261812	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.L576P	KIT	p.L576P	4:55593661..55593661	PMID: 17372901, 18448188	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PHKG2#p.M260I	PHKG2	p.M260I	16:30767818..30767820/c.778..780/p.260R	.	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	RET#p.M918T	RET	p.M918T	10:43617416..43617416	PMID: 21470995	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 21394667	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.N822K	KIT	p.N822K	4:55599340..55599340	PMID: 21394667	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	.	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PHKG2#p.V50M	PHKG2	p.V50M	16:30762479..30762481/c.148..150/p.50F	.	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.V559A	KIT	p.V559A	4:55593610..55593610	PMID: 22261812	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.V559D	KIT	p.V559D	4:55593610..55593610	PMID: 22261812	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 25182956	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.V603D	KIT	p.V603D	4:55594022..55594022	.	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.W557R	KIT	p.W557R	4:55593603..55593603	PMID: 22261812	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.W557R	KIT	p.W557R	4:55593603..55593603	PMID: 12960119	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.Y553N	KIT	p.Y553N	4:55593591..55593591	PMID: 23375402	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.Y553N	KIT	p.Y553N	4:55593591..55593591	PMID: 21969494	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.Y823D	KIT	p.Y823D	4:55599341..55599341	PMID: 24205792	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.577_579del	KIT	p.P577_D579 del	4:55593663..55593671	PMID: 15201427	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT#p.V560del	KIT	p.V560 del	4:55593612..55593614	PMID: 15201427	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	CA9:over	CA9	CA9 overexpression	9:35673914..35674369..exon1,35675524..35675574..exon2,35675747..35675938..exon3,35676050..35676213..exon4,35676283..35676396..exon5,35677776..35677863..exon6,35679171..35679349..exon7,35679840..35680005..exon8,35680099..35680146..exon9,35680739..35680841..exon10,35680951..35681072..exon11	PMID: 24086736	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	VEGFR2:over	FLT1	FLT1 overexpression	13:28877253..28877515..exon1,28880804..28880919..exon2,28882969..28883074..exon3,28885716..28885879..exon4,28886119..28886245..exon5,28891624..28891744..exon6,28893549..28893681..exon7,28895589..28895732..exon8,28896388..28896506..exon9,28896916..28897093..exon10,28901588..28901697..exon11,28903741..28903875..exon12,28908151..28908276..exon13,28913294..28913447..exon14,28919571..28919698..exon15,28931680..28931832..exon16,28942664..28942810..exon17,28959011..28959178..exon18,28963787..28964251..exon19,28963922..28964251..exon20,28971086..28971215..exon21,28973180..28973265..exon22,28979906..28980041..exon23,29001285..29001465..exon24,29001878..29002068..exon25,29004176..29004314..exon26,29005262..29005457..exon27,29007945..29008102..exon28,29008184..29008367..exon29,29012347..29012492..exon30,29041029..29041276..exon31,29041647..29041764..exon32,29068906..29069030..exon33	PMID: 24086736, 21478036	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	VEGFR1:over	FLT1	FLT1 overexpression	13:28877253..28877515..exon1,28880804..28880919..exon2,28882969..28883074..exon3,28885716..28885879..exon4,28886119..28886245..exon5,28891624..28891744..exon6,28893549..28893681..exon7,28895589..28895732..exon8,28896388..28896506..exon9,28896916..28897093..exon10,28901588..28901697..exon11,28903741..28903875..exon12,28908151..28908276..exon13,28913294..28913447..exon14,28919571..28919698..exon15,28931680..28931832..exon16,28942664..28942810..exon17,28959011..28959178..exon18,28963787..28964251..exon19,28963922..28964251..exon20,28971086..28971215..exon21,28973180..28973265..exon22,28979906..28980041..exon23,29001285..29001465..exon24,29001878..29002068..exon25,29004176..29004314..exon26,29005262..29005457..exon27,29007945..29008102..exon28,29008184..29008367..exon29,29012347..29012492..exon30,29041029..29041276..exon31,29041647..29041764..exon32,29068906..29069030..exon33	PMID: 24086736, 21478036	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	HIF1A:over	HIF1A	HIF1A overexpression	14:62162472..62162567..exon1,62164518..62164682..exon2,62187086..62187300..exon3,62187089..62187300..exon4,62188216..62188382..exon5,62188446..62188551..exon6,62193413..62193546..exon7,62194160..62194383..exon8,62199125..62199252..exon9,62200845..62201013..exon10,62203596..62203837..exon11,62204794..62205101..exon12,62207212..62207355..exon13,62207462..62207916..exon14,62211412..62211541..exon15,62212398..62212545..exon16,62213641..62213707..exon17,62213641..62213853..exon18	PMID: 24086736	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT:amp	KIT	KIT amplification	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 22261812	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性降低	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT:550-592	KIT	KIT mutation in exon 11	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18955458	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT:788-828	KIT	KIT mutation in exon 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 23840364	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	耐药性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT:550-592,627-664	KIT	KIT mutation in exon 9,11,13,14 or 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18421059, 21642685, 21690468, 22261812	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT:449-514,550-592,627-664,664-714,788-828	KIT	KIT mutation in exon 9,11,13,14 or 17	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	FDA	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	KIT::wildtype:.	KIT	KIT wildtype	4:55524131..55524258..exon1,55561667..55561957..exon2,55564439..55564741..exon3,55565785..55565942..exon4,55569879..55570068..exon5,55573253..55573463..exon6,55575579..55575715..exon7,55589739..55589874..exon8,55592012..55592214..exon9,55592012..55592226..exon10,55593373..55593500..exon11,55593571..55593718..exon12,55593978..55594103..exon13,55594166..55594297..exon14,55595490..55595661..exon15,55597483..55597595..exon16,55598026..55598174..exon17,55599225..55599368..exon18,55602653..55602785..exon19,55602876..55602996..exon20,55603330..55603456..exon21,55604584..55604773..exon22	PMID: 18955458	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	MKI67:over	MKI67	MKI67 overexpression	10:129897403..129897529..exon1,129899511..129899975..exon2,129900832..129907697..exon3,129908631..129908807..exon4,129909898..129910090..exon5,129910180..129910319..exon6,129910386..129910719..exon7,129911680..129911876..exon8,129913181..129914281..exon9,129914744..129914810..exon10,129917506..129917593..exon11,129921134..129921270..exon12,129921344..129921443..exon13,129923829..129923981..exon14	PMID: 24086736	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PDGFRA:552-596,631-668,814-854	PDGFRA	PDGFRA (552-596,631-668,814-854)	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	NCCN guidelines	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PDGFRA:over	PDGFRA	PDGFRA overexpression	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	PMID: 24086736	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	PDGFRA::wildtype:.	PDGFRA	PDGFRA wildtype	4:55100588..55100675..exon1,55106169..55106292..exon2,55124885..55124994..exon3,55124913..55124994..exon4,55127251..55127589..exon5,55129823..55130104..exon6,55131075..55131226..exon7,55133445..55133637..exon8,55133708..55133918..exon9,55136789..55136925..exon10,55138550..55138697..exon11,55139693..55139907..exon12,55140687..55140802..exon13,55140997..55141150..exon14,55143544..55143669..exon15,55144052..55144183..exon16,55144518..55144692..exon17,55146472..55146659..exon18,55147737..55147898..exon19,55151527..55151663..exon20,55151997..55152140..exon21,55153586..55153718..exon22,55154955..55155075..exon23,55155165..55155291..exon24,55156469..55156731..exon25,55161281..55161489..exon26	PMID: 18955458	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	RET__.	RET	RET fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 28447912	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	RET__TPCN1	RET	RET-TPCN1 fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 21470995	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Sunitinib	Sunitinib (舒尼替尼)	KIT;VEGFR1(FLT1);VEGFR2(KDR);VEGFR3(FLT4)	VHL:.	VHL	VHL oncogenic mutation	3:10183481..10183881..exon1,10188187..10188330..exon2,10191460..10191699..exon3	PMID: 18635227	NCT01164202:Phase 2|Phase 3:Completed:No publish||NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.||NCT00247676:Phase 2:Completed:No publish||NCT00806663:Phase 2:Completed:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	是（非本癌种）	敏感性增加	肾癌; 胃肠道间质瘤; 胰腺癌	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	MAP2K2#p.C125S	MAP2K2	p.C125S	19:4110583..4110583	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	BRAF#p.K601R	BRAF	p.K601R	7:140453133..140453133	PMID: 23248257, 22805292, 23248257	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	MAP2K2#p.L46F	MAP2K2	p.L46F	19:4117584..4117584	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	BRAF#p.L597R	BRAF	p.L597R	7:140453145..140453145	PMID: 23248257, 22805292, 23248257	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	MAP2K2#p.N126D	MAP2K2	p.N126D	19:4110581..4110581	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	MAP2K1#p.Q56P	MAP2K1	p.Q56P	15:66727451..66727451	PMID: 26582713	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	MAP2K2#p.V35M	MAP2K2	p.V35M	19:4117617..4117617	PMID: 24265153	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	FDA	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	BRAF#p.V600K	BRAF	p.V600K	7:140453136..140453137	FDA	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	BRAF#p.V600R	BRAF	p.V600R	7:140453136..140453137	PMID: 23248257, 22805292, 23248257	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 26936308	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24576830, 2524381	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	NF1:del	NF1	NF1 deletion	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 26325560	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性降低	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	BRAF__.	BRAF	BRAF fusion	7:140434346..140434580..exon1,140439601..140439756..exon2,140449076..140449228..exon3,140453064..140453203..exon4,140453976..140454043..exon5,140476701..140476898..exon6,140477780..140477885..exon7,140481365..140481503..exon8,140482810..140482967..exon9,140487337..140487394..exon10,140494097..140494277..exon11,140500151..140500291..exon12,140501201..140501370..exon13,140507749..140507872..exon14,140508681..140508805..exon15,140534398..140534682..exon16,140549900..140550022..exon17,140624355..140624553..exon18	PMID: 24727320, 24345920, 20526349	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	PMID: 27338794	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 26936308	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 24576830, 2524381	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	NF1:.	NF1	NF1 oncogenic mutation	17:29422277..29422397..exon1,29482990..29483154..exon2,29486017..29486121..exon3,29490193..29490404..exon4,29496898..29497025..exon5,29508429..29508517..exon6,29508717..29508813..exon7,29509515..29509693..exon8,29527429..29527623..exon9,29528044..29528187..exon10,29528418..29528513..exon11,29533247..29533399..exon12,29541458..29541613..exon13,29546012..29546146..exon14,29548857..29548957..exon15,29548857..29549058..exon16,29550451..29550595..exon17,29552102..29552278..exon18,29553442..29553712..exon19,29554225..29554319..exon20,29554530..29554634..exon21,29556032..29556493..exon22,29556842..29557002..exon23,29557267..29557410..exon24,29557849..29557953..exon25,29559080..29559217..exon26,29559707..29559909..exon27,29560009..29560241..exon28,29562618..29562800..exon29,29562925..29563049..exon30,29575991..29576147..exon31,29579945..29580028..exon32,29585351..29585530..exon33,29586039..29586157..exon34,29587376..29587543..exon35,29588718..29588885..exon36,29592236..29592367..exon37,29652827..29653280..exon38,29654506..29654867..exon39,29657303..29657526..exon40,29661845..29662059..exon41,29663340..29663501..exon42,29663642..29663942..exon43,29664375..29664610..exon44,29664826..29664908..exon45,29665032..29665167..exon46,29665711..29665833..exon47,29667512..29667673..exon48,29670016..29670163..exon49,29676127..29676279..exon50,29677190..29677346..exon51,29679264..29679442..exon52,29683467..29683610..exon53,29683967..29684118..exon54,29684276..29684397..exon55,29685487..29685650..exon56,29685976..29686043..exon57,29687494..29687731..exon58,29701020..29701223..exon59	PMID: 26325560	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性降低	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	PRKCH:amp;ABL1__BCR	ABL1	PRKCH amplification + ABL1-BCR fusion	9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12	PMID: 25186176	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trametinib	Trametinib (曲美替尼)	MAP2K1;MAP2K2	PRKCH:amp;ABL1__BCR	PRKCH	PRKCH amplification + ABL1-BCR fusion	14:61788769..61789192..exon1,61857932..61858016..exon2,61909818..61909989..exon3,61912399..61912454..exon4,61915871..61915980..exon5,61917549..61917699..exon6,61919933..61920081..exon7,61923883..61924047..exon8,61924213..61924407..exon9,61952209..61952384..exon10,61995782..61995941..exon11,61997114..61997323..exon12,62014450..62014614..exon13,62016392..62016599..exon14;ABL1范围：9:133589656..133589852..exon1,133710783..133710922..exon2,133729440..133729634..exon3,133730177..133730493..exon4,133738139..133738432..exon5,133747505..133747610..exon6,133748236..133748434..exon7,133750244..133750449..exon8,133753791..133753964..exon9,133755444..133755554..exon10,133755876..133756061..exon11,133759345..133761120..exon12;BCR范围：22:23523097..23524436..exon1,23595975..23596177..exon2,23603126..23603251..exon3,23603531..23603737..exon4,23610584..23610712..exon5,23613708..23613789..exon6,23615257..23615330..exon7,23615810..23615971..exon8,23626153..23626295..exon9,23627209..23627398..exon10,23629335..23629475..exon11,23630273..23630369..exon12,23631693..23631818..exon13,23632515..23632610..exon14,23634717..23634835..exon15,23637200..23637352..exon16,23651600..23651680..exon17,23652500..23652630..exon18,23653873..23654033..exon19,23655063..23655218..exon20,23656144..23656270..exon21,23656728..23656911..exon22,23657609..23657759..exon23	PMID: 25186176	NCT02292173:Phase 1:Recruiting:No publish||NCT02042443:Phase 2:Completed:No publish||NCT02070549:Phase 1:Recruiting:No publish||NCT02465060:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	黑色素瘤	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.C311R	ERBB2	p.C311R	17:37873594..37873594	PMID: 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.C311R	ERBB2	p.C311R	17:37873594..37873594	PMID: 23220880, 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.C334S	ERBB2	p.C334S	17:37868279..37868279	PMID: 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.D769H	ERBB2	p.D769H	17:37880261..37880261	PMID: 23220880, 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.D769Y	ERBB2	p.D769Y	17:37880261..37880261	PMID: 23220880, 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.E321G	ERBB2	p.E321G	17:37868241..37868241	PMID: 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB3#p.G284R	ERBB3	p.G284R	12:56481922..56481922	PMID: 23680147	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.G309E	ERBB2	p.G309E	17:37868205..37868205	PMID: 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.G309E	ERBB2	p.G309E	17:37868205..37868205	PMID: 23220880, 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.G776L	ERBB2	p.G776L	17:37880997..37880998delinsCT	PMID: 16775247	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB3#p.P262H	ERBB3	p.P262H	12:56481857..56481857	PMID: 23680147	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB3#p.Q809R	ERBB3	p.Q809R	12:56490980..56490980	PMID: 23680147	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	AKT3#p.R247C	AKT3	p.R247C	1:243736308..243736308	PMID: 26645663	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.R896C	ERBB2	p.R896C	17:37881616..37881616	PMID: 23220880, 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.S310F	ERBB2	p.S310F	17:37868208..37868208	PMID: 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.S310F	ERBB2	p.S310F	17:37868208..37868208	PMID: 23220880, 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.S310Y	ERBB2	p.S310Y	17:37868208..37868208	PMID: 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2#p.S310Y	ERBB2	p.S310Y	17:37868208..37868208	PMID: 23220880, 22908275	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2::consequence::inframe_insertion:A775YVMA,::inframe_insertion:G776VC	ERBB2	ERBB2 inframe insertion (A775YVMA),inframe insertion (G776VC)	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	ASCO 2017 (abstr 8510)	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ARID1A:amp;ANXA1:over	ANXA1	ARID1A amplification + ANXA1 overexpression	9:75773401..75773527..exon1,75773600..75773729..exon2,75774234..75774349..exon3,75775168..75775302..exon4,75775708..75775819..exon5,75777687..75777787..exon6,75778381..75778458..exon7,75780021..75780135..exon8,75781002..75781118..exon9,75782402..75782481..exon10,75783937..75784080..exon11,75784956..75785073..exon12	PMID: 27172896	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ARID1A:amp;ANXA1:over	ARID1A	ARID1A amplification + ANXA1 overexpression	1:27022844..27024041..exon1,27056131..27056364..exon2,27057632..27058105..exon3,27059156..27059293..exon4,27087336..27087597..exon5,27087864..27087974..exon6,27088632..27088820..exon7,27089453..27089786..exon8,27092701..27092867..exon9,27092937..27093067..exon10,27094270..27094500..exon11,27097599..27097827..exon12,27098980..27099133..exon13,27099292..27099488..exon14,27099826..27099997..exon15,27100060..27100218..exon16,27100282..27100399..exon17,27100809..27101721..exon18,27101460..27101721..exon19,27102057..27102208..exon20,27105503..27107297..exon21	PMID: 27172896	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ARID1A:.;ANXA1:over	ANXA1	ARID1A oncogenic mutation + ANXA1 overexpression	9:75773401..75773527..exon1,75773600..75773729..exon2,75774234..75774349..exon3,75775168..75775302..exon4,75775708..75775819..exon5,75777687..75777787..exon6,75778381..75778458..exon7,75780021..75780135..exon8,75781002..75781118..exon9,75782402..75782481..exon10,75783937..75784080..exon11,75784956..75785073..exon12	PMID: 27172896	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ARID1A:.;ANXA1:over	ARID1A	ARID1A oncogenic mutation + ANXA1 overexpression	1:27022844..27024041..exon1,27056131..27056364..exon2,27057632..27058105..exon3,27059156..27059293..exon4,27087336..27087597..exon5,27087864..27087974..exon6,27088632..27088820..exon7,27089453..27089786..exon8,27092701..27092867..exon9,27092937..27093067..exon10,27094270..27094500..exon11,27097599..27097827..exon12,27098980..27099133..exon13,27099292..27099488..exon14,27099826..27099997..exon15,27100060..27100218..exon16,27100282..27100399..exon17,27100809..27101721..exon18,27101460..27101721..exon19,27102057..27102208..exon20,27105503..27107297..exon21	PMID: 27172896	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	FDA	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	FDA	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26022204	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26099744, 19840887	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性降低	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 21380780	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 20003286, 12525520	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 21107682, 20975068	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 21558407	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 25294905	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:amp	ERBB2	ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	http: //ascopubs.org/doi/full/10.1200/PO.16.00055	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:over	ERBB2	ERBB2 overexpression	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	ASCO 2013 (abstr 2605), 26104654	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:over	ERBB2	ERBB2 overexpression	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	FDA	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2:over	ERBB2	ERBB2 overexpression	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	FDA	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	ERBB2::consequence::inframe_insertion:775-881	ERBB2	ERBB2 proximal exon 20	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26598547;ASCO 2017 (abstr 9071)	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	HGF:amp;ERBB2:amp	ERBB2	HGF amplification + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 22850551	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	HGF:amp;ERBB2:amp	HGF	HGF amplification + ERBB2 amplification	7:81331846..81332083..exon1,81334695..81334861..exon2,81334952..81335079..exon3,81335592..81335753..exon4,81336595..81336690..exon5,81339452..81339569..exon6,81340786..81340845..exon7,81346537..81346691..exon8,81350050..81350173..exon9,81355195..81355343..exon10,81358910..81359105..exon11,81372207..81372275..exon12,81372658..81372797..exon13,81374305..81374446..exon14,81381377..81381588..exon15,81381425..81381573..exon16,81381425..81381588..exon17,81386494..81386629..exon18,81387997..81388130..exon19,81392012..81392198..exon20,81399189..81399337..exon21	PMID: 22850551	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	KRAS:.	KRAS	KRAS oncogenic mutation	12:25362678..25362855..exon1,25368324..25368504..exon2,25378537..25378717..exon3,25380157..25380356..exon4,25398197..25398368..exon5	ASCO 2015 (abstr 3508);NCT01104571;EBCC10	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	MET:amp;ERBB2:amp	ERBB2	MET amplification + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 26432108	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	MET:amp;ERBB2:amp	ERBB2	MET amplification + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 22850551	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	MET:amp;ERBB2:amp	ERBB2	MET amplification + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 22850551; PMID: 26432108	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	MET:amp;ERBB2:amp	MET	MET amplification + ERBB2 amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 26432108	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	MET:amp;ERBB2:amp	MET	MET amplification + ERBB2 amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 22850551	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	MET:amp;ERBB2:amp	MET	MET amplification + ERBB2 amplification	7:116339088..116340348..exon1,116371711..116371923..exon2,116371761..116371923..exon3,116379993..116380148..exon4,116380895..116381089..exon5,116395398..116395579..exon6,116397480..116397603..exon7,116397681..116397838..exon8,116398502..116398684..exon9,116399380..116399554..exon10,116399434..116399554..exon11,116403093..116403332..exon12,116409688..116409855..exon13,116409688..116409963..exon14,116411541..116411718..exon15,116411892..116412053..exon16,116414924..116415175..exon17,116417432..116417533..exon18,116418819..116419021..exon19,116422031..116422161..exon20,116423347..116423533..exon21,116435698..116435855..exon22,116435930..116436228..exon23	PMID: 22850551; PMID: 26432108	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	耐药性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	PIK3CA:.;ERBB2:amp	ERBB2	PIK3CA oncogenic mutation + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 27091708	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	PIK3CA:.;ERBB2:amp	PIK3CA	PIK3CA oncogenic mutation + ERBB2 amplification	3:178916563..178916975..exon1,178917467..178917697..exon2,178919067..178919338..exon3,178921321..178921587..exon4,178922280..178922386..exon5,178927372..178927498..exon6,178927963..178928136..exon7,178928208..178928363..exon8,178935987..178936132..exon9,178936973..178937075..exon10,178937348..178937533..exon11,178937726..178937850..exon12,178938763..178938955..exon13,178941858..178941985..exon14,178942477..178942619..exon15,178943739..178943838..exon16,178947049..178947240..exon17,178947781..178947919..exon18,178948002..178948174..exon19,178951871..178952202..exon20	PMID: 27091708	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	PTEN:.;ERBB2:amp	ERBB2	PTEN oncogenic mutation + ERBB2 amplification	17:37855762..37855850..exon1,37856441..37856574..exon2,37863209..37863404..exon3,37863232..37863404..exon4,37864563..37864797..exon5,37865560..37865715..exon6,37866055..37866144..exon7,37866328..37866464..exon8,37866582..37866744..exon9,37868170..37868310..exon10,37868564..37868711..exon11,37871528..37871622..exon12,37871688..37871799..exon13,37871982..37872202..exon14,37872543..37872696..exon15,37872757..37872868..exon16,37873562..37873743..exon17,37873562..37873787..exon18,37876029..37876097..exon19,37879561..37879720..exon20,37879780..37879923..exon21,37880154..37880273..exon22,37880968..37881174..exon23,37881291..37881467..exon24,37881569..37881665..exon25,37881949..37882116..exon26,37882804..37882922..exon27,37883057..37883266..exon28,37883537..37883810..exon29,37883931..37884000..exon30,37883931..37884347..exon31	PMID: 27091708	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Trastuzumab	Trastuzumab (曲妥珠单抗)	ERBB2;ERBB3;EGFR	PTEN:.;ERBB2:amp	PTEN	PTEN oncogenic mutation + ERBB2 amplification	10:89623656..89623870..exon1,89623851..89624315..exon2,89624176..89624315..exon3,89653771..89653876..exon4,89685259..89685324..exon5,89690792..89690856..exon6,89692759..89693018..exon7,89711864..89712026..exon8,89711923..89712026..exon9,89717599..89717786..exon10,89720640..89720885..exon11,89725033..89725279..exon12	PMID: 27091708	NCT03319459:Phase 1:Recruiting:No publish||NCT01953926:Phase 2:Recruiting:No publish	是（非本癌种）	否	敏感性增加	乳腺癌; 胃癌或食管胃结合部癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	RET#p.C634W	RET	p.C634W	10:43609950..43609950	PMID: 20065189, 22025146	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	RET#p.M918T	RET	p.M918T	10:43617416..43617416	PMID: 20065189, 22025146	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	RET#p.M918T	RET	p.M918T	10:43617416..43617416	PMID: 20368568	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	ABL1#p.V299L	ABL1	p.V299L	9:133747531..133747531	PMID: 26924578	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	BRAF#p.V600E	BRAF	p.V600E	7:140453136..140453136	PMID: 20065189, 22025146	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	RET#p.V804M	RET	p.V804M	10:43614996..43614996	PMID: 24336963	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	耐药性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	RET	RET (618,620,634,768,791,891,918,C634W,M918T)	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 20065189, 22025146	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	RET__.	RET	RET fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 28447912	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vandetanib	Vandetanib (凡德他尼)	VEGFA;EGFR;RET	RET__TPCN1	RET	RET-TPCN1 fusion	10:43572656..43572789..exon1,43595896..43596180..exon2,43597779..43598087..exon3,43600389..43600651..exon4,43601813..43602029..exon5,43604468..43604688..exon6,43606644..43606923..exon7,43607536..43607682..exon8,43608290..43608421..exon9,43608993..43609133..exon10,43609917..43610194..exon11,43612021..43612189..exon12,43613810..43613938..exon13,43614968..43615203..exon14,43615518..43615661..exon15,43617383..43617474..exon16,43619108..43619266..exon17,43620320..43620440..exon18,43622012..43622180..exon19,43622012..43622252..exon20,43623549..43623767..exon21	PMID: 21470995	NCT00508001:Phase 2:Completed:No publish	是（非本癌种）	否	敏感性增加	甲状腺癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.D473G	SMO	p.D473G	7:128849190..128849190	PMID: 25759020, 25306392	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.D473H	SMO	p.D473H	7:128849189..128849189	PMID: 25759020, 25306392	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.D473H	SMO	p.D473H	7:128849189..128849189	PMID: 19726788, 25759019	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.G497W	SMO	p.G497W	7:128850226..128850226	PMID: 25759020, 25306392	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.L412F	SMO	p.L412F	7:128846398..128846398	PMID: 25759020, 25306392	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.Q477E	SMO	p.Q477E	7:128849201..128849201	PMID: 25759020, 25306392	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.W281C	SMO	p.W281C	7:128845546..128845546	PMID: 25759020, 25306392	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	SMO#p.W535L	SMO	p.W535L	7:128850341..128850341	PMID: 25759020, 25306392	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	耐药性增加	基底细胞癌	II
Vismodegib	Vismodegib (维莫德吉)	SMO	PTCH1:.	PTCH1	PTCH1 oncogenic mutation	9:98209143..98209743..exon1,98211340..98211615..exon2,98212112..98212232..exon3,98215749..98215912..exon4,98218547..98218705..exon5,98220284..98220585..exon6,98221871..98222075..exon7,98224127..98224290..exon8,98229387..98229717..exon9,98231022..98231445..exon10,98232084..98232223..exon11,98238305..98238451..exon12,98239030..98239149..exon13,98239818..98239994..exon14,98240326..98240478..exon15,98241271..98241439..exon16,98242240..98242382..exon17,98242661..98242880..exon18,98244220..98244332..exon19,98244405..98244495..exon20,98247956..98248147..exon21,98247956..98248166..exon22,98268678..98268891..exon23,98270432..98270693..exon24,98278740..98278803..exon25,98278894..98279152..exon26	PMID: 19726763, 19726761	NCT02465060:Phase 2:Recruiting:No publish||NCT01546519:Phase 1:Completed:No publish	是（非本癌种）	否	敏感性增加	基底细胞癌	II
CF-102	CF-102	A3AR	.	.	.	.	.	NCT00790218:Phase 1|Phase 2:Completed:No publish||NCT02128958:Phase 2:Recruiting:No publish	否	否	.	肝癌;慢性丙型肝炎	III
CS-1008	CS-1008（TRAIL-R2单抗）	TRAIL-R2	.	.	.	.	.	NCT01033240:Phase 2:Completed:No publish	否	否	.	肝癌	III
